Review

Merging the Multi-Target Effects of Phytochemicals in Neurodegeneration: From Oxidative Stress to Protein Aggregation and Inflammation

Fiona Limanaqi 1,†, Francesca Biagioni 2,†, Federica Mastroiacovo 2, Maico Polzella 3, Gloria Lazzeri 1,* and Francesco Fornai 1,2,*

1 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy; f.limanaqi@studenti.unipi.it
2 Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Via Atinense 18, 86077 Pozzilli, Italy; francesca.biagioni@neuromed.it (F.B.); federica.mast@neuromed.it (F.M.)
3 Aliveda Laboratories, Viale Karol Wojtyla 19, 56042 Crespina Lorenzana, Italy; maico@aliveda.com
* Correspondence: gloria.lazzeri@unipi.it (G.L.); francesco.fornai@neuromed.it (F.F.)
† These authors equally contributed.

Received: 28 September 2020; Accepted: 16 October 2020; Published: 20 October 2020

Abstract: Wide experimental evidence has been provided in the last decade concerning the neuroprotective effects of phytochemicals in a variety of neurodegenerative disorders. Generally, the neuroprotective effects of bioactive compounds belonging to different phytochemical classes are attributed to antioxidant, anti-aggregation, and anti-inflammatory activity along with the restoration of mitochondrial homeostasis and targeting alterations of cell-clearing systems. Far from being independent, these multi-target effects represent interconnected events that are commonly implicated in the pathogenesis of most neurodegenerative diseases, independently of etiology, nosography, and the specific misfolded proteins being involved. Nonetheless, the increasing amount of data applying to a variety of neurodegenerative disorders joined with the multiple effects exerted by the wide variety of plant-derived neuroprotective agents may rather confound the reader. The present review is an attempt to provide a general guideline about the most relevant mechanisms through which naturally occurring agents may counteract neurodegeneration. With such an aim, we focus on some popular phytochemical classes and bioactive compounds as representative examples to design a sort of main highway aimed at deciphering the most relevant protective mechanisms which make phytochemicals potentially useful in counteracting neurodegeneration. In this frame, we emphasize the potential role of the cell-clearing machinery as a kernel in the antioxidant, anti-aggregation, anti-inflammatory, and mitochondrial protecting effects of phytochemicals.

Keywords: polyphenols; terpenes; alkaloids; autophagy; mitophagy; immunoproteasome; inflammasome; exosomes; prionoid; neuroprotection

1. Introduction

In the last century, plant-derived bioactive compounds, known as phytochemicals, have received growing attention for their preventive and therapeutic potential in various human disorders, ranging from cancer to metabolic and neurodegenerative disorders [1–7]. The amount of data applying to a variety of neurodegenerative disorders joined with the multiple effects exerted by phytochemicals, and the innumerable plant-derived neuroprotective agents provides a plethora of information, which may rather confound the reader. The present review is designed to provide a guideline about the most relevant mechanisms through which various classes of naturally occurring agents may counteract neurodegeneration. It being actually impossible to review each of these compounds and
effects, we will design a sort of main highway to decipher those protective mechanisms which make phytochemicals potentially useful in counteracting neurodegeneration.

In the brain, phytochemicals produce several biological effects such as modulation of neurotransmitter metabolism and release, growth factor induction, antioxidant, and anti-inflammatory activity, as well as regulation of mitochondrial homeostasis, and maintenance of proteostasis, which is bound, at least in part, to targeting alterations of cell-clearing systems [1–9]. When considered individually, none of the effects produced by phytochemicals is expected to fully achieve neuro-health benefits and/or therapeutic efficacy, since different etiological factors may combine to produce a chain of intermingled pathological events in neurodegeneration [1–13]. Far from being independent, the multi-target effects of phytochemicals are interconnected and implicated in most neurodegenerative disorders. These include alterations of glucose metabolism and redox imbalances occurring in the cellular environment, which may contribute to promoting mitochondrial damage and protein misfolding, meanwhile affecting protein quality control [10,13,14]. In fact, oxidative compounds and sugar residues may alter secondary protein structure and conformation, thus fostering protein misfolding and aggregation, which is exacerbated when the cell-clearing systems autophagy and proteasome are impaired [10,15]. Oxidative stress, coupled with the impaired removal of altered mitochondria by autophagy, which is named mitophagy, also contributes to the accumulation of damaged mitochondria which, in turn, fuels the release of reactive oxygen species (ROS) and pro-apoptotic caspases [16,17].

In this frame, an interdependency exists between oxidative/inflammatory events, mitochondrial damage, protein aggregation, and alterations of autophagy and proteasome, which are promiscuously implicated in various neurodegenerative proteinopathies [7,10,14,17–21]. It is now widely accepted that autophagy and proteasome are altered in both patients and experimental models of neurodegeneration, and their inhibition in experimental models reproduces key pathological features of neurodegeneration [7,10,21–24]. Chronic oxidative stress, exaggerated inflammation, and protein aggregation converge to alter cell-clearing systems which, in turn, may fuel the accumulation of damaged mitochondria as well as the aggregation and extracellular spreading of potentially toxic proteins and oxidative/inflammatory mediators [10,24–29]. These stand as hallmark pathological events in neurodegeneration, independently of disease etiology, symptoms, neuronal phenotypes, and the specific misfolded protein being involved. Therefore, this applies to Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease (HD), brain ischemia, spinal bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD), age-related macular degeneration (AMD), and many others [7,10,24–35].

In most neurodegenerative conditions, the affected protein(s) tend to aggregate, being released, and spread according to autocrine, paracrine, and endocrine fashion, which makes these proteins reminiscent of prions (which explains the term prionoids) [36,37]. Prionoid release occurs mostly when these proteins accumulate in the cell being oxidized/aggregated and glycated [38–40]. If this occurs in the presence of a failure in the cell-clearing systems, and mostly the autophagy-lysosome pathway, the extracellular release is the unconventional solution to overcome danger-associated molecular patterns (DAMPs), including advanced glycation end products (AGE), AGE-modified proteins, high mobility group box 1 (HMGB1), depolarized mitochondria leaking ROS, and also fragments of mitochondrial DNA (mtDNA) [10,38,41–45]. The irreversible glycation and oxidation of proteins and lipids produce AGEs which, similar to fragments of mtDNA and HMGB1, are released extracellularly either as free compounds or via exosomes that derive from the fusion of autophagy-lysosome vacuoles with the plasma membrane [10,38,45]. In neighboring cells, including neurons and glia, these DAMPs bind to toll-like receptors (TLRs) and AGE receptors (RAGEs), thus activating downstream oxidative and inflammatory signaling pathways which converge in altering cell-clearing systems, such as nuclear factor (NF)-κB, JAK/STAT, protein kinase C (PKC), and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) [28,44,46–48]. In this way, indigested DAMPs may perpetuate oxidative and inflammatory damage in the surrounding neuronal milieu.
In this frame, it is remarkable that the common neuroprotective, antioxidant, and anti-inflammatory effects produced by several phytochemicals are associated with rescuing autophagy, meanwhile counteracting behavioral alterations, mitochondrial damage as well as intracellular accumulation and release of potentially detrimental substrates [3,49–71]. As recently reviewed, the neuroprotective effects of phytochemicals involve also a double-faceted, yet controversial modulation of the proteasome pathway, which will not be discussed in detail herewith [9]. Instead, we will briefly discuss the potential role of the immunoproteasome, a cytokine-inducible proteasome isofrom recruited by the same phytochemical-targeted inflammatory pathways which impinge on autophagy.

The present review summarizes potential key mechanisms underlying the neuroprotective effects of phytochemicals in the attempt to bridge their antioxidant, anti-inflammatory, and anti-aggregation properties with modulation of cell-clearing systems. In this frame, we will emphasize cell-to-cell communication mechanisms, discussing how different classes of phytochemicals, through common mechanisms converging onto cell-clearing pathways, may affect the extracellular release of proteins, and oxidative and inflammatory mediators. This is important both in baseline conditions as a health-promoting strategy, and a potential restorative strategy that follows up various neurological insults.

2. An Overview of Neuroprotective Phytochemical Classes

Phytochemicals are widely present, mostly in combination, in edible plants and plant products including grains, oilseeds, beans, leaf waxes, bark, roots, spices, fruits, and vegetables. Based on their chemical structures and characteristics, phytochemicals are generally classified into major categories, namely carbohydrates, lipids, steroids, phenolic compounds (polyphenols), terpenes, alkaloids, and other nitrogen-containing compounds (e.g., glucosinolates and polyamines) [1,72,73]. Given the multitude of phytochemical classes and compounds, in the present review, we focus on the effects of a few neuroprotective categories, each one briefly summarized for the sake of clarity in the following schematic paragraph.

2.1. Polyphenols

Phenolic compounds or polyphenols are characterized by one or more aromatic rings owning one or more hydroxyl groups. Besides their roles in plant reproduction and growth, as well as defense mechanisms against plant pathogens, phenolic compounds provide multiple health benefits in animals and humans. Polyphenols are widely found in species, seeds, fruits, and vegetables, such as apple, red grape, olive, strawberry, pineapple, banana, peach, lemon, orange, pear, grapefruit, broccoli, soybean, spinach, yellow onion, red pepper, carrot, cabbage, potato, lettuce, celery, and cucumber [72]. While representing the most widely distributed bioactive compounds in the human diet, phenolic compounds are intensely investigated for their potential health benefits in various brain disorders. In fact, among innumerable antioxidant compounds, dietary polyphenols have received growing attention, since their consumption has been associated with promising indications against age-related cognitive decline and risk of developing neurodegeneration [74,75]. According to their chemical structure, polyphenols are further categorized into flavonoids, stilbenes, phenolic acids, and lignans. In turn, flavonoids can be sub-classified into flavonols, flavones, flavanols, flavanones, anthocyanidins, and isoflavonoids, according to the structure of the heterocycle C ring. Examples of compounds which are mostly investigated for their potential neuroprotective effects include quercetin, kaempferol and myricetin (flavonols) [50–54,76–86], scutellarin, baicalein, and apigenin (flavones) [50,55,56,61,87–90], catechins, epicatechin, and epigallocatechin gallate (EGCG, flavanols), as well as genistein (isoflavonoid), and silymarin (flavonolignan) [63,91–96]. The stilbene group is best exemplified by resveratrol, a well-known phenolic compound found in red wine, grape, and virgin olive oil, which has shown remarkable neuroprotective and anti-aging properties in a plethora of experimental models [50,58,59,65,69,97–102]. Finally, phenolic acids, which can be subdivided into hydroxybenzoic acids (such as syringic and gallic acids) [103–105] and hydroxycinnamic acids (such as ferulic, caffeic, and chlorogenic acids, including the derivatives rosmarinic acid, salvianolic acid,
and curcumin), have shown encouraging results in various experimental models of neurodegeneration, neurotoxicity and neurological insults [3,54,57,62,66,70,106,107].

2.2. Terpenes

Similar to polyphenols, terpenes are classified into many categories based on the number of carbon atoms and iso-prene residues present in their structure, ranging from monoterpenes to polyterpenes [108]. As some triterpenes are steroidal in nature, they are known as triterpenoid saponins, among which bacosides/bacopasides and withanolides represent two major bioactive compounds of nootropic and neuroprotective plant extracts [3,71,109–113]. Within the tetraterpenoid group, carotenoids (such as α-/β-carotene, lutein, zeaxanthin, and fucoxanthin) occurring widely in orange fruits and vegetables, are worth citing for their neuroprotective effects in various experimental models of neurodegeneration, especially AMD [7,114,115].

2.3. Alkaloids

Alkaloids are naturally occurring compounds containing carbon, hydrogen, nitrogen, and usually oxygen. Alkaloids can be further divided into several classes based on the sources, pharmacokinetics, and chemical structures [116]. They are primarily found in Solanaceae (nightshades), Papaveraceae (poppies family), Ranunculaceae (buttercups), and Amaryllidaceae (amaryllis) plant families [116]. A variety of phytochemicals belonging to the alkaloid group has proven beneficial effects in several models of neurodegeneration, among which berberine (an isoquinoline alkaloid) and caffeine (a xanthine alkaloid) are worth mentioning [60,67,117–121].

2.4. Other Nitrogen-Containing Phytochemicals

Finally, among the nitrogen-containing group of phytochemicals, examples of potentially beneficial compounds in neurodegeneration/neurotoxicity here taken into account are sulforaphane (belonging to the glucosinolates group and found in cruciferous vegetables such as broccoli, cabbage, brussels sprouts, and cauliflower) [64,122–124] and spermine/spermidine (a polyamine found in soybean seeds) [68,125–127].

In the following sections, we provide an overview of the main molecular mechanisms through which different phytochemicals provide neuroprotection in experimental models of neurodegeneration, that is countering oxidative stress, mitochondrial alterations, neuroinflammation, and protein aggregation. For each of these effects, we discuss the potential role of the cell-clearing machinery as a key where the multi-target effects of phytochemicals may converge onto. Actually, attributing the neuroprotective effects of phytochemicals to single specific mechanisms may be a pure educational artifact, since pathogenic mechanisms, as well as the neuroprotective effects, do communicate (Figure 1).

**Figure 1.** A general overview of the mechanisms of action of phytochemicals in neurodegenerative diseases. Intermingled as pieces of a puzzle, the multi-target effects of phytochemicals in the brain include anti-oxidant, mitochondrial protecting, anti-apoptotic, anti-aggregation, and anti-inflammatory activity.
3. Phytochemicals and Oxidative Stress

Oxidative stress results from a decrease in the antioxidant system’s response coupled with increased production of ROS, including free radicals such as superoxide anion (O$_2^-$) and hydroxyl radical (OH), and also non-radical species such as hydrogen peroxide (H$_2$O$_2$), singlet oxygen (O$_2$), and so forth. Oxidative stress, that is, when the level of intracellular ROS exceeds the defense mechanisms, represents a common hallmark of various brain disorders, ranging from psychiatric to neurological and vascular-related brain disorders [3,7,10,13–17,19,25,32,128]. Persistent and sustained oxidative stress may contribute to neuronal injury through ROS-mediated oxidative damage at the level of various biomolecules, including proteins, lipids, and nucleic acids within neurons and glia. The deleterious effects of ROS in the brain are bound to the abundance of polyunsaturated fatty acids, transition metal ions, and also to the high metabolic rate of excitatory and oxidation-prone neurotransmitters, such as dopamine and glutamate, which makes brain cells highly susceptible to ROS-mediated damage [129].

In the last decades, the search for an effective and potentially safe strategy to combat oxidative stress-mediated neuronal damage has increasingly prompted the investigation of naturally occurring compounds as antioxidant agents. The attenuation of oxidative stress by bioactive compounds belonging to different classes of phytochemicals including (i) flavonoids (quercetin, kaempferol and myricetin, scutellarin, baicalin, apigenin, catechins, epigallocatechin, and genistein) [52,61,81–83,88,94,130–137]; (ii) phenolic acids (syringic, gallic, caffeic, chlorogenic and salvianolic acids, and curcumin) [70,103–105,138–143]; (iii) flavonolignans (silymarin) [96]; (iv) stilbenes (resveratrol) [59,65,97,98,144]; (v) terpenes (bacosides/bacopasides, withanolides, and the carotenoids lutein and zeaxanthin) [7,110,113,115,145–147]; (vi) alkaloids (berberine and caffeine) [148,149]; (vii) glucosinolates (sulforaphane) and polyamines (spermine/spermidine) [123,124,150] have been associated with neuroprotection in both in vitro and in vivo models of ALS, PD, AD, ischemia/reperfusion, brain trauma/hemorrhage, AMD, and diabetic retinopathy, as well as H$_2$O$_2$-, lipopolysaccharide (LPS)-, pesticide-, and metal-induced neurotoxicity.

Roughly, the antioxidant mechanisms of phytochemicals consist of (1) promoting ROS scavenging and the suppression of intracellular ROS accumulation [82,130,136,137,145]; and/or (2) potentiation of antioxidant defense mechanisms [83,131–135,138,140,144]. A common molecular mechanism through which these natural compounds boost antioxidant defenses consists of activating the Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (Nrf2/ARE), which induces the expression of various ROS-dissipating and antioxidant enzymes [83,131–135,138,140,143,144,148]. These include heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase (NQO1), as well as γ-glutamyl-cysteine synthetase (GCS), which promotes the synthesis of endogenous glutathione (GSH), as well as GSH synthetase (GSS), GSH reductase (GSR), GSH peroxidase (GSH-Px), superoxide dismutase (SOD), catalase (CAT), thioredoxin (THx), and cysteine-glutamate exchanger, the subunit of glutamate-cysteine ligase (GCL). Moreover, some phytochemicals, such as quercetin, have been shown to induce paraoxonase 2 (PNO2), a ubiquitously expressed enzyme in the human brain, which is associated with neuroprotection and the suppression of oxidative stress owing to its strategic placement within mitochondria [76,151]. Phytochemicals also prevent ROS-mediated lipid peroxidation, which is known to exacerbate oxidative stress through lipid-derived radicals [81,132,134,137,140,145]. This is documented in various experimental models of neurodegeneration and neurotoxicity, where different phytochemicals can prevent the generation of malondialdehyde (MDA) and hydroxynonenal (HNE), the final products of peroxidation of unsaturated fatty acids [81,132,134,137,140,144,145].

3.1. Autophagy-Related Antioxidant Effects of Phytochemicals

3.1.1. An Overview of the Autophagy Pathway

In concert with the proteasome system, autophagy orchestrates the turnover of various cellular components, encompassing proteins, lipids, sugars, as well as whole organelles, such as mitochondria,
portions of the endoplasmic reticulum (ER), synaptic vesicles, and intracellular pathogens [21,24,41]. Substrate engulfment within autophagy vacuoles may either occur as a non-selective process or involve adaptor/receptor proteins such as SQSTM1/p62, which shuttle ubiquitinated cargoes, and also the proteasome itself, to the forming autophagosome [10,152]. By fusing with endosomes and multivesicular bodies (MVBs), the autophagosome gives rise to the amphisome, which then fuses with the lysosome, where cargo degradation eventually occurs, while some metabolic by-products are recycled. When lysosome dysfunction or the suppression of fusion of autophagosomes/MVBs with the lysosome occurs, inadequate digestion of intracellular cargoes may promote their exosomal release as an unconventional solution aimed at getting rid of potentially deleterious material [10,42,153].

The fine steps of autophagy progression are regulated in response to the metabolic needs of the cells by different nutrient-sensing pathways and through various autophagy-related gene (ATG) products. The phosphatidylinositol 3-kinase (PI3K)/AKT and the Unc-51 like autophagy activating kinase-1 (ATG1/ULK1) complexes are key to promote autophagy initiation [21,41]. The mammalian target of rapamycin complex 1 (mTORC1) and the 5′ AMP-activated Protein Kinase (AMPK) inhibit and promote autophagy through inhibition and activation of the ULK1 complex, respectively [10,21,41]. Phosphorylation of the PI3K-III regulatory subunit Beclin-1 (ATG6, BECN1), the formation of the BECN1/VPS34/ATG14 complex, and phosphorylation of activating molecule in BECN1 regulated autophagy (AMBR1) by ULK1 are equally important in finely tuning the autophagy process while balancing autophagy with MAPK-related apoptosis [154]. Conversion of ATG8 (LC3 in mammals) into LC3I, lipidation of LC3I into LC3II, and eventually, the incorporation of LC3II into the phagophore membrane, is crucial for the autophagy vacuoles to mature and seal, thus ensuring proper cargo engulfment [10,21,41]. Again, activation of the NAD-dependent deacetylase Sirtuin-1 (SIRT1) promotes autophagy initiation via de-acetylation of ATG5, ATG7, LC3, and activation of the transcription factor Forkhead Box O3 (FOXO3) [49]. Finally, autophagy induction occurs following the inhibition of Glycogen Synthase Kinase 3 Beta (GSK3-β) [29,155,156] or activation of the transcription factor EB (TFEB), which acts either in cooperation with or independently of mTORC1 to regulate lysosomal activation and autophagosome-lysosome fusion [123].

Autophagy impairment is documented in a plethora of neurodegenerative disorders, where besides protein aggregation it is bound to oxidative stress, mitochondrial damage, and neuroinflammation [10,24–29,41]. During cellular stresses, such as acute oxidative stress, mitochondrial alterations, and para-inflammation, autophagy is promptly recruited as a compensatory attempt to cope with increasing protein overload and grant cell survival [10,14]. Compensatory activation of autophagy may also follow proteasome impairment, which may occur due to an oxidative-related disassembling of proteasome subunits and a decrease in its catalytic capacity [10]. Nonetheless, it is worth mentioning that misinterpretations of the autophagy status may also occur in this frame, leading to confounding outcomes. In detail, increased levels of LC3II, which is generally employed as a gold standard autophagy marker, may witness for either an increase or a decrease of the autophagy flux [19,32]. This in turn may underlie either the accumulation of stagnant vacuoles or misplacement of LC3 within cell compartments other than autophagy vacuoles [19,32]. Thus, assessment of LC3II levels through semi-quantitative techniques can lead to results misinterpretation unless it is coupled with other autophagy markers or ultrastructural immune-labeling [19,157].

As shown in various experimental models of neurodegeneration, a failure in the autophagy machinery may predispose to neuronal injury due to extreme oxidative damage intermingling with protein overload and neuroinflammation, while rescuing autophagy may confer protection to grant cell survival [7,10,21,24,28,29]. It is remarkable that a wide variety of phytochemicals, including phenolic compounds such as anthocyanins, stilbenes (resveratrol), monophenols (caffeic acid, gallic acid), glucosides and flavonoids (catechin, epicatechin, quercetin, myricetin), and also nitrogen-containing compounds (berberine and spermine), are capable of stimulating autophagy to confer neuroprotection through either Akt/mTOR inhibition or AMPK/SIRT1 or TFEB activation [3,49–71]. Thus, in the
next section, we discuss evidence bridging the antioxidant effects of these compounds with autophagy-related neuroprotection.

3.1.2. Phytochemicals Bridging Autophagy Induction and Prevention of Oxidative Stress

While being promptly recruited as a compensatory mechanism to cope with cell survival in conditions of mild oxidative stress, autophagy may be progressively and severely affected by persistent and sustained oxidative stress. In fact, abnormal amounts of ROS and lipid peroxidation products can inhibit autophagy flux [158–161]. In line with this, autophagy failure in experimental models of neurodegeneration (e.g., AD, PD, and AMD), is associated with elevated levels of ROS, oxidized carbonyl proteins, oxidized cholesterol, deposition of lipid peroxidation products, and apoptosis [160–164]. Conversely, in the retina, in aged neurons, as well as in PD and AD mouse brains, autophagy activation goes along with reduced oxidative damage, decreased lipid peroxidation, and increased cell viability [161,162,164,165]. The ability of autophagy inducers to upregulate the levels of antioxidant mediators GSH, SOD2, NRF2, and NQO1 while decreasing ROS and lipid peroxide products supports the link between autophagy and antioxidant defenses [14,161–165]. In line with this, the antioxidant, neuroprotective effects of several phytochemicals, such as curcumin, catechins, resveratrol, caffeic acid, sulforaphane, resveratrol, lutein/zeaxanthin, and apigenin are associated with autophagy induction [3,7,54,70,106,123]. This occurs via mTOR inhibition or, AMPK/SIRT1 or TFEB activation in various experimental models including PD, brain ischemia, AMD, and spinocerebellar ataxia [3,7,54,70,106,123]. These effects are mostly bound to Nrf2 activation, which acts as a hub in bridging reduction of oxidative stress, autophagy induction, and inhibition of neuronal apoptosis. In line with this, increased oxidative stress occurs in the brain of mice featuring impaired autophagy due to Atg7 ablation, which in turn promotes p53 activation and neurodegeneration [166]. When Atg7 is deleted concomitantly with Nrf2, animals’ death rapidly occurs, indicating an interdependency between autophagy, p53, and Nrf2 stress response mechanisms [166]. The interplay between autophagy and Nrf2 involves also molecular mechanisms that may be independent of redox status. In detail, the adaptor autophagy protein p62 binds to ubiquitinated proteins, including the Nrf2 inhibitor Keap1 [167,168]. This leads to Keap1 degradation via autophagy, thus leaving Nrf2 free to accumulate and translocate in the nucleus where it promotes the transcription of antioxidant and detoxifying genes [167,168]. Again, antioxidant defense and autophagy rescue by phytochemicals may be bound to a dual-action upon GSK3-β inhibition and Nrf2 activation [133,169].

4. Phytochemicals and Mitochondrial Damage

Being placed at the interface between oxidative stress and neuronal bioenergetics, mitochondrial alterations represent a hallmark of neurodegeneration [170]. Mitochondria are the best-known adenosine triphosphate (ATP)-producing organelles at baseline while representing the main intracellular source of ROS and pro-apoptotic caspases when damaged or impaired. Oxidative stress resulting from an increased rate of ROS production and lipid peroxidation leads to mitochondrial dysfunctions while promoting mutations and deletions of mtDNA, which occurs in various age-related and neurodegenerative disorders [4,45,171]. In detail, the high amount of ROS being generated around mtDNA during oxidative phosphorylation contributes to mtDNA damage and fragmentation. Once released extracellularly as cell-free circulating mtDNA fragments (ccf-mtDNA), these may act as pro-inflammatory mediators in the neuronal milieu [45], which will be dealt with in Section 6.

As recently reviewed, many phytochemicals, such as resveratrol, curcumin, naringin, genistein, EGCG can protect mtDNA function and integrity while inhibiting its release, highlighting how these effects could be applied the prevention or treatment in neurodegenerative disorders [4]. In line with this, neuroprotective, antioxidant, and anti-apoptotic effects of most phytochemicals go along with mitochondrial protection. The latter is associated with preserved mitochondrial membrane potential and ATP production, reduced mitochondrial fragmentation, increased SOD activity, reduction of ROS and ROS-induced damage, up-regulation of Bcl-2, as well as down-regulation
of Bax, p53, and caspase-3 [52,82,83,137,144,145,147,172]. The beneficial effects of phytochemicals against mitochondrial damage in models of neurodegeneration/neurotoxicity are also evident at the ultrastructural level, whereby a reduction in mitochondrial swelling, loss of cristae, and chromatin condensation are observed [83].

**Autophagy-Related Mitochondrial Protection by Phytochemicals**

Besides preventing ROS-induced mitochondrial damage, ensuring the clearance of damaged mitochondria (mitophagy) along with the biogenesis of novel ones (mitochondriogenesis) is crucial to preventing neurodegeneration [35,173,174]. Intriguingly, the imbalance between mitophagy and mitochondriogenesis is bound to autophagy failure, highlighting the pleiotropic effects of autophagy upon the preservation of mitochondrial functions [35]. In detail, autophagy orchestrates mitophagy and mitochondriogenesis through various molecular pathways, including mTOR, GSk3-β, AMPK/SIRT-1, PCG1α, and the downstream effector Nrf2 [35,175,176]. While LC3 along with the adaptor proteins p62, Parkin, and PINK-1 polarize within altered mitochondria to promote mitophagy, Nrf2 contributes to shuttling the signal from mitophagy-prone altered mitochondria towards the nucleus to induce mitochondrial biogenesis [174,176,177].

In this frame, mitochondrial protection achieved by several phytochemicals is bound to autophagy induction. For instance, resveratrol and quercetin stimulate mitochondriogenesis through SIRT1-dependent activation of PGC-1α and NRF2, and also through upregulating the autophagic flux via inhibition of extracellular signal-regulated kinase (ERK) signaling pathway [58,176]. The combination of catechin and quercetin, through upregulation of PGC-1α, results in a synergistic improvement in neuronal mitochondrial function and cytoprotection against ischemic injury [178]. Again, in in vitro and in vivo models of mitochondrial toxin-induced PD, phytochemicals such as kaempferol and baicalein provide anti-apoptotic and antioxidant neuroprotective effects through the enhancement of mitochondrial turnover by autophagy, which is abolished when autophagy is pharmacologically inhibited [52,55]. These effects are also reported for bacosides/bacopasides, which induce Parkin-dependent mitophagy to exert anti-senescence and anti-apoptotic effects [71]. While inducing mitophagy, Parkin-dependent ubiquitination also triggers the degradation of the pro-apoptotic protein Bax [179]. Anti-apoptotic effects that are bound to enhanced mitophagy are reported in mice models of brain ischemia for phytochemicals such as kaempferol, baicalin, and curcumin [85,180,181]. Again, in models of subarachnoid hemorrhage, EGCG prevents mitochondrial damage and mtDNA alterations, which goes along with enhanced autophagy flux and mitophagy to prevent cytochrome c-mediated intrinsic apoptotic pathway [182]. Spermidine-induced activation of PINK1-dependent mitophagy is associated with memory and behavioral performance improvement and prolonged lifespan in AD and PD worms [183]. Similarly, in cell models of glucose-induced damage, berberine promotes mitochondriogenesis and mitophagy through the restoration of AMPK-dependent autophagy flux, though this remains to be documented in brain cells specifically [184]. In this frame, a remarkable overlap emerges between the mechanisms through which natural remedies such as phytochemicals, physical exercise, and caloric restriction do provide widespread beneficial effects through amelioration of oxidative stress and mitochondrial function [185], which are tightly bound to the autophagy-dependent orchestration of mitochondrial dynamics [186].

5. Phytochemicals and Proteostasis

5.1. Alterations of Proteostasis in Neurodegeneration

Examples of aggregation-prone proteins in neurodegenerative disorders include alpha-synuclein (α-syn) in synucleinopathies such as PD and multiple system atrophy (MSA); amyloid-beta (Aβ) and hyper-phosphorylated tau in AD; prion protein (PrP) in Creutzfeldt-Jakob disease; polyglutamine-expanded huntingtin in HD; polyglutamine-expanded androgen receptor (ARpolyQ) in SBMA; TAR-DNA-binding protein of 43 kDa (TDP-43) in ALS/FTD, as well as TDP-43, and Cu/Zn
superoxide dismutase (SOD), fused in sarcoma (FUS), among others, in ALS [10,25]. Although a certain degree of precision medicine can be drawn from the knowledge of proteinopathies, the promiscuous co-occurrence of these proteins in different brain disorders and mixed brain syndromes has been puzzling the molecular basis of disease-specificity [187]. In fact, α-syn aggregation occurs in classic synucleinopathies and also in HD, brain ischemia, ALS, and AD, where it co-localizes with TDP-43, Aβ, and tau [188–191]. Likewise, protein inclusions which stain for either TDP-43 or tau are detected in FTD patients [192], while SOD1 positive inclusions may occur in PD cases [193]. Also, in AMD, a neurodegenerative disorder of the macula, proteins such as α-syn and Aβ are detected in “drusen”, which are amorphous proteinaceous deposits occurring between the retinal pigment epithelium and the photoreceptors [7]. Finally, besides classic prion diseases, insoluble aggregates of PrP, are found in models of PD, which is bound to oxidative dopamine metabolism similar to what was reported for α-syn [194,195]. These pieces of evidence converge in that a generalized defect in proteostasis plays a leading role across different neurodegenerative disorders independently of nosography and symptomatology. As a further common mechanism associated with altered proteostasis, the hypothesis of a prionoid propagation has been proposed for these diseases [37,187]. In fact, similar to PrP, misfold-prone proteins such as α-syn, tau, Aβ, huntingtin, SOD-1, TDP-43, and FUS can form insoluble, intracellular aggregates in a self-templating manner [10,36,37,187]. All these proteins share prion-like properties, that is the tendency of spontaneous conversion of the normal isoform into abnormal ones, and subsequent spreading via exocytotic, cell-to-cell transmission [10,36,37,187].

In this frame, the cellular environment besides the genetic background plays a key role. In particular, oxidative stress represents a key event promoting protein aggregation through altering protein conformation. Oxidative compounds, including ROS, are known to alter protein structure and conformation through oxidation of SH groups into S-S disulfide bonds, thus contributing to protein misfolding, aggregation, and cell-to-cell spreading [15,196]. Proteins can also be modified indirectly by conjugation with breakdown products of fatty acid peroxidation [197]. Again, sugar residues bind to proteins leading to a spontaneous reaction to form a Shift’s base, fostering post-translational glycation of proteins such as α-syn, Aβ, tau, huntingtin, and SOD-1 [38,198]. Glycation eventually leads to the formation of advanced glycation end-products (AGEs), which may derive either directly from the binding of the proteins to methylglyoxal, glyoxalase, and 3-deoxyglucosone compounds, or from a cascade of spontaneous reactions. Glycation can promote amyloid protein aggregation and induce the formation of oligomer species through covalent AGE-derived cross-links, thus contributing to cell toxicity [199]. Remarkably, due to their bulky structure, insoluble molecules, including AGEs, large protein aggregates, and AGE-derived cross-linked proteins, cannot be digested by the proteasome [27,40]. This fuels an increase in the amount of oxidized/glycated and aggregates proteins, which, in turn, may contribute to engulfing the autophagy compartments [38,40,195]. In this way, AGEs coupled with autophagy failure make protein aggregates irreversible and protease-resistant meanwhile increasing their propensity to spread from cell to cell. Since AGEs and AGE-modified proteins are substrates of the autophagy-lysosome system, autophagy failure contributes to the extracellular release and spreading of undigested, potentially toxic substrates [38,43]. In neighboring cells, AGE receptors (RAGEs) allow binding and entering of AGEs and AGE-modified proteins. These can either aggregate and persist in the donor cell or move out to spread the disease within various RAGE-expressing recipient cells, including brain endothelial cells, microglia, astrocytes, and neurons [10,38]. The binding of AGEs with RAGEs triggers a variety of transduction mechanisms, which may bridge alterations in cell-clearing mechanisms with oxidative, and apoptotic events [44,47,48]. In detail, RAGEs trigger activation of PKC, NF-kB, JAK2/STAT1, and AKT/mTOR pathways, which promote a vicious cycle of inflammatory and oxidative reactions while altering autophagy and the proteasome [10,44]. Therefore, antioxidant/glycation compounds that can prevent protein aggregation are expected to provide beneficial effects in neurodegeneration.
5.2. Anti-Aggregation Mechanisms of Phytochemicals

Recently, phytochemicals attracted much attention for their anti-aggregation, anti-oxidative/glycoxidative properties being associated with neuroprotection in various neurodegenerative proteinopathies. For instance, quercetin inhibits α-syn aggregation while preventing further α-syn fibrillation [200]. This is due to the covalent binding with α-syn, which leads to quercetin-α-syn adducts conferring increased hydrophilicity to the covalently modified α-syn oligomers or monomers [200]. These quercetin/α-syn interactions are key to disaggregating the preformed fibrils through detaching into stable oligomers [200]. Similar to quercetin, baicalein, EGCG, gallic acids, ferulic acid derivatives, curcumin, dihydromyricetin, and salvianolic acid prevent α-syn aggregation and fibrillation in vitro and in vivo, which is associated with neuroprotection in various PD models [54,87,142,201–205].

Through direct phytochemical–protein interaction, baicalin, EGGC, and quercetin derivatives prevent SOD1 misfolding and aggregation [78,79]. Binding of phytochemicals to SOD1 also reduces the cytotoxicity of SOD1 fibrils, either by arresting fibrils elongation or by blocking the fibrillar core regions on the intermediate species [78]. Berberine also prevents TDP-43 and ARpolyQ aggregates formation, which may be relevant for neuroprotection in ALS and SBMA, respectively [121].

Again, curcumin, resveratrol, rosmarinic acid, and myricetin act as anti-prion agents by binding β-sheet-rich PrP oligomers and fibrils [206–209]. Among these compounds, rosmarinic acid and myricetin were recently shown to be the most effective anti-prion fibril compounds by inhibiting seeding and production of toxic prion fibril while stabilizing non-toxic PrP oligomers [209].

Again, curcumin, myricetin, rosmarinic acid, ferulic acid, quercetin, scutellarin, berberine, resveratrol, and sulforaphane inhibit tau hyperphosphorylation and Aβ formation and destabilize Aβ preformed fibrils, meanwhile decreasing the levels of extracellular and intracellular Aβ in models of AD [76,210–215]. Recent studies aimed at elucidating the mechanisms by which polyphenols affect aggregation showed that the flavonoids gallolatechin gallate and theaflavin could completely inhibit Aβ aggregation, while the two stilbenes resveratrol and its glucoside derivative piceid could also suppress Aβ aggregation, though to a much lesser extent [216]. This could be attributed to the presence of more aromatic rings and hydroxyl groups within flavonoids compared with stilbenes. Intriguingly, resveratrol was shown to accelerate the formation of Aβ fibrils before decreasing fibrillation, suggesting specific effects for different phytochemicals upon Aβ kinetics [216]. Recently, much attention has been paid to the neuroprotective effects of rosmarinic acid and salvianolic acid, which can effectively and selectively target the whole cascade of Aβ formation, from amyloid precursor protein (APP) formation to aggregation, fibrillation, and Aβ-induced neurotoxicity [217]. Concerning Aβ formation, these compounds suppress the key amyloidogenic pathway enzyme β-secretase (BACE1), while augmenting the non-amyloidogenic pathway enzyme ADAM10 (α-secretase) [217].

Remarkably, an additional mechanism by which phytochemicals may preserve proteostasis to counteract protein aggregation and toxicity is through anti-glycation effects. Bioactive compounds such as genistein, chlorogenic acid, gallic acid, resveratrol, melatonin, and curcumin can block AGE formation, thus preventing AGE-derived protein glycation and AGE interaction with RAGEs [218,219]. This occurs by protecting endogenous proteins from AGE-derived cross-linking, either by trapping di-carbonyl compounds such as methylglyoxal and glyoxalase or by promoting the formation of protein–phytochemical complexes [218,219].

5.3. Autophagy-Related Anti-Aggregation Effects of Phytochemicals

Besides phytochemical-protein interaction, the induction of autophagy fostering degradation of misfolded/aggregated proteins represents a key mechanism underlining the neuroprotective effects of phytochemicals. Caffeic acid, curcumin, dihydromyricetin, salvianolic acid, and spermine, through autophagy activation following mTOR inhibition or Beclin-1 recruitment, prevent α-syn aggregation and provide neuroprotection against α-syn-induced neurotoxicity in PD models [54,62,126,220]. The beneficial effects of these compounds are instead occluded by pharmacological autophagy inhibitors [54,62,126,220]. Curcumin, while reducing the levels of oxidized proteins in PD models,
also promotes proteasome activation, thus abolishing the inhibitory effect exerted by oxidative neurotoxicants on this degradative system [221]. Again, kaempferide and kaempferol reduce the intracellular mutant SOD1 aggregates, which is associated with cytoprotection and autophagy induction via the AMPK-mTOR pathway [84].

Through the induction of autophagy, quercetin antagonizes Aβ-induced neurotoxicity [222], while quercetin nanoparticles promote the fusion of autophagosomes and lysosomes, which is associated with enhanced clearance of Aβ, and cytoprotection from Aβ-induced toxicity [51]. Similar to quercetin, curcumin exerts anti-fibrillogenic effects and counteracts the aggregation of tau and Aβ through mTOR-dependent autophagy activation [223,224]. Similar effects in AD mice models are provided by berberine, which reduces hyperphosphorylation of tau and promotes its clearance through autophagy induction via Akt/GSK3-β and PI3K/Bclin-1 pathways [118]. Berberine, through autophagy induction, also prevents the cognitive decline and reduces Aβ plaque deposition in mice AD models [119]. In detail, berberine treatment decreases the levels of extracellular and intracellular Aβ while activating autophagy, as evident by the increased levels of LC3II, Beclin-1, Vps34, and Cathepsin-D, along with decreased levels of p62, Bcl-2, APP, and BACE1 [119].

Berberine also reverses the formation of insoluble TDP-43 aggregates through the activation of either mTOR-dependent autophagy or the proteasome pathway [120,121]. In HD models, berberine reduces the accumulation of mutant huntingtin by enhancing autophagy-dependent degradation, which is associated with improved motor function and prolonged survival of HD mice [225].

Finally, mTOR/AMPK-related autophagy activation following curcumin, caffeine, or sulforaphane treatment counteracts PrP aggregation and protects neuronal cells against PrP-induced toxicity, while inhibiting autophagy (through ATG5 knockdown, or 3-methyladenine (3-MA) and wortmannin administration) occludes the neuroprotective effects of these compounds [60,64,208].

A summary of the phytochemical-targeted pathogenic events discussed so far is provided in Figure 2.
Antioxidants 2020, 9, 1022 12 of 34

(A) summarizes the cascade of pathogenic events implicated in neurodegeneration. Oxidative stress arises from a decrease of antioxidant defense and a concomitant increase in the levels of reactive oxygen species (ROS) and lipid peroxidation products, such as malondialdehyde (MDA). This leads both to mitochondrial dysfunctions and protein oxidation/glycation fostering the accumulation of damaged mitochondria and the release of mitochondrial ROS, caspases, and mitochondrial DNA (mtDNA) fragments on the one hand and protein aggregation on the other. Altered intracellular substrates, including damaged mitochondria, and ubiquitinated proteins, and advanced glycation endproducts (AGEs) are targeted for degradation by autophagy and the proteasome. Nonetheless, the high amount of ROS along with the increasing amount of large protein aggregates and AGE-modified proteins contributes to impairing the proteasome while engulfing autophagy/lysosome vacuoles. This occludes the removal of altered substrates and impedes the release of the antioxidant factor Nrf2 from Keap1, thus fueling a vicious cycle of oxidative-related pathological events (B) summarizes the neuroprotective mechanisms of phytochemicals (blue stars). These consist of decreasing oxidative stress through upregulating anti-oxidant defense and decreasing ROS and MDA levels, preserving mitochondrial function, preventing protein oxidation/glycation, and aggregation through either direct molecular binding or increased degradation via autophagy induction. This includes Keap2 degradation and Nrf2 activation, which contributes to counteracting oxidative stress and mitochondrial damage along with promoting mitophagy and mitobiogenesis.

6. Phytochemicals and Inflammatory Pathways

Inflammation is critically involved in the pathogenesis of neurodegenerative disorders and it is tightly linked to oxidative stress, as well as abnormal DAMPs accumulation and their extracellular spreading [10,33,41,45]. Intriguingly, a paucity of studies exists investigating the effects of phytochemicals in the prion-like, cell-to-cell spreading of potentially toxic, and pro-inflammatory proteins. For instance, resveratrol reduces the exosome-mediated release of mutant huntingtin, though the role of cell clearing systems was not directly investigated [226]. Again, berberine, through autophagy induction, provides neuroprotection in AD models by reducing both the intracellular and extracellular accumulation of Aβ [119], which implies that it might prevent the cell-to-cell spreading of Aβ. In this frame, it is expected that, by potentiating the clearance of prionoids, phytochemicals may prevent the extracellular spreading of potentially toxic proteins and oxidative/inflammatory mediators (Figure 3). This is key since transduction mechanisms that are triggered by the binding of DAMPs (including oxidized proteins, AGEs, and mtDNA) to RAGEs and TLRs, do foster pro-inflammatory and pro-apoptotic reactions that go along with alterations of cell-clearing systems [10,44,45,227]. In detail, TLRs- and RAGEs-induced activation of PKC, NF-kB, JAK2/STAT1, and AKT/mTOR pathways converge in promoting neuroinflammation through NF-kB-related inflammasome (NLRP3) activation within neurons, microglia, and astrocytes [10,44,45,227]. This goes along with the activation of astrocytes and microglia, which produce and release pro-inflammatory cytokines (IL-1β, TNFα), complement components, acute-phase proteins, as well as iNOS and NO while recruiting immune cells within the CNS milieu and promoting neuronal damage.

Inflammatory/oxidative stimuli in general, and RAGEs and TLRs-induced cascades in particular, converge into recruiting the immunoproteasome, an alternative, (oxidative-, and cytokine-inducible), immune-related proteasome [10,18,44]. Abnormal persistence of immunoproteasomes within neurons or glial cells may perpetuate inflammation and immune responses within the CNS milieu to promote neuronal damage in various neurological disorders [7,18,228–230]. This is associated with enhanced antigen processing of endogenous proteins such as α-syn, and subsequent activation of T-cell responses against glial and neuronal cells, which under excessive pro-inflammatory conditions do upregulate MHC molecules just like antigen-presenting cells [228,229]. Remarkably, molecular pathways that recruit the immunoproteasome, such as PKC, JAK-STAT, NF-κB, RAGE/TLR, and mTORC1 are known to impinge on the autophagy machinery [10,18,28,44,46–48]. The very same immunoproteasome may contribute to impair autophagy through ATG5 and PTEN degradation [231,232]. In line with this, immunoproteasome recruitment along with the concomitant impairment of autophagy
flux is described during inflammation and oxidative damage occurring in neurodegeneration and neurotoxicity [18]. This is key since autophagy plays a balancing role intended to avoid excessive tissue damage while ensuring a measured anti-inflammatory response [233]. Powerful pro-inflammatory effects occur when autophagy is impaired within neurons or glial cells, while rescuing autophagy may mitigate both oxidative damage and excessive inflammatory response by counteracting the COX2-NF-kB-NLRP3 pathway, for instance [28,29,53,234]. This suggests that by rescuing autophagy, phytochemicals may counteract inflammation both by preventing the extracellular release of undigested pro-inflammatory DAMPs and by counteracting NF-kB-NLRP3 activation, which is expected to blunt immunoproteasome-dependent immune reactions as well.

![Figure 3. Phytochemicals, cell-clearing machinery, and neuro-inflammation. By rescuing alterations of autophagy, phytochemicals prevent the intracellular accumulation of danger-associated molecular patterns (DAMPs, including ROS, damaged mitochondria, fragments of mtDNA, and aggregated proteins), potentially preventing their extracellular release and the subsequent neuroinflammatory events being triggered in neighboring neurons and glial cells. In fact, in neighboring cells, DAMPs bind to RAGE and TLR, triggering pro-inflammatory, pro-apoptotic cascades that contribute to recruiting the immunoproteasome while altering autophagy flux. By degrading self-proteins within antigenic sites, the immunoproteasome contributes to cytotoxic auto-immune attack, while autophagy impairment contributes to intracellular DAMPs accumulation and extracellular spreading. In this frame, phytochemicals provide beneficial effects by downregulating pro-inflammatory cascades such as AGE/RAGEs, JAK/STAT, mTOR, HMGB1/TLR-4, and NF-kB/NLRP3 while up-regulating AMPK/SIRT1/PGC-1α and Nrf2, which are bound, at least in part, to autophagy activation and blunting of immunoproteasome activity.

Is There a Role of Autophagy and Immunoproteasome in the Anti-Inflammatory Effects of Phytochemicals?

Several recent studies highlighted the role of natural compounds in models of neuroinflammation (Table 1).
Table 1. Natural compounds providing beneficial effects in models of neuroinflammation: a summary of recent studies.

| Models of Neuroinflammation | Anti-Inflammatory Phytochemicals |
|-----------------------------|----------------------------------|
| Parkinson's disease (PD)    | Kaempferol [53]                  |
| SNCA- and LPS-induced neurodegeneration in mice [53] | Dihydromyricetin and |
| Cells transfected with C-terminal modified α-syn and BAC-α-syn-GFP transgenic mice [54] | Salvianolic acid [54] |
| 6-OHDA-treated rats [95]    | Silymarin [95]                   |
| MPTP-treated rats [235] and mice [236] | Quercetin [235] |
| Alzheimer's disease (AD)    | 2-pentadecyl-2-oxazoline [236] |
| APP/PS1 transgenic mice [237] | Liquiritigenin [237] |
| Aβ oligomer-treated mice [238] | Gelsemine [238] |
| 5XFAD mice [239]            | Phloroglucinol [239] |
| Aβ25-35 peptide-treated BV2 murine microglia cells and human Aβ1-42-expressing flies [240] | Arabidopsis extract (caffeic acid, kaempferol, quercetin, synapic acid, luteolin) [240] |
| Traumatic Brain Injury (TBI) | 2-pentadecyl-2-oxazoline [241] |
| 2-pentadecyl-2-oxazoline [241] | Artemisin [242] |
| Spinal Cord Injury (SCI)    | Berberine [67]                   |
| 2-pentadecyl-2-oxazoline [241] | Curcumin [57] |
| Brain hemorrhage            | Curcumin [243]                   |
| Prechiasmatic cistern blood injection [243] and internal carotid rupture [101] | Genistein [93] |
| Brain ischemia/hypoperfusion | Resveratrol [101] |
| Middle Cerebral Artery Occlusion (MCAO) [93,244-246] | 2-pentadecyl-2-oxazoline [244] |
| Lipopolysaccharide (LPS)    | Palmitoylethanolamide-luteolin [245] |
| Salvianolic acid [46]       | Syringaldehyde [246] |
| Resveratrol                  |                          |
| SOD1<sup>G93A</sup> mice [112,248,249] | Ashwagandha [112] |
| Amyotrophic Lateral Sclerosis (ALS) | Protocatechuic acid [248] |
| Salvanolic acid [250]       | Anthocyanin-enriched |
| Anxiety and depression      | strawberries extract [249] |
| Chronic mild stress, and olfactory bulbectomized rat model of depression [250,251] |                              |

Neuroprotective and anti-inflammatory effects of phytochemicals are associated, either directly or indirectly, with modulation autophagy and (immuno)-proteasome pathways (Figure 3). For instance, kaempferol counteracts neuroinflammation and provides neuroprotection by inhibiting NLRP3 inflammasome activation and IL-1β secretion in vivo [53]. These effects are directly associated with a rescue of autophagy within microglia and subsequent degradation of ubiquitinated NLRP3, which is prevented by either ATG5 knockdown or treatment with autophagy inhibitors [53].

Resveratrol, while providing neuroprotection through autophagy induction [59,97,99,100] inhibits NLRP3 inflammasome activation and IL-1β secretion by downregulating the downstream signals of AGE-RAGE, including p38, JNK, and NF-κB [102]. Resveratrol also promotes microglia polarization toward the anti-inflammatory M2 phenotype via PGC-1α upregulation and STAT2/6 downregulation [69]. Again, through the downregulation of the pro-inflammatory TLR-4-NF-κB signaling, resveratrol protects against hypoxic neuronal damage, which is accompanied by SIRT1-dependent inhibition of HMGB1 extracellular release [101].

Similar to resveratrol, curcumin alleviates neuroinflammation by promoting microglia phenotype shift toward M2 and downregulation of the TLR-4-NF-κB pathway [243]. Curcumin-targeted glial activation, inflammatory infiltration, and pro-inflammatory cytokine release following neurological insults are associated with mTOR-dependent autophagy activation, while autophagy inhibition abrogates the beneficial effects of curcumin [57].

Silymarin and quercetin protect against neurotoxicant-induced apoptosis and neuro-inflammation by counteracting the overexpression of TLR-4 and COX-2 signaling pathways [95,253]. Similarly, in PD models of α-syn-induced toxicity, dihydromyricetin, and salvianolic acid exhibit anti-aggregation
and anti-inflammatory activities, which are associated with autophagy induction and attenuation of glia-mediated neuroinflammation [54].

Salvianolic acid, by rescuing autophagy, also produces anti-depressant effects while downregulating the expression of pro-inflammatory cytokines and NLRP3 inflammasome in LPS-treated mice [66].

Again, ashwagandha-induced neuroprotection in mice models of ALS is associated with autophagy rescue and anti-inflammatory effects, including reduced glial activation and phosphorylation of NF-κB along with downregulation of multiple pro-inflammatory cytokines/chemokines [112].

Finally, berberine and genistein promote neuronal survival by exerting anti-apoptotic and anti-inflammatory effects which are associated with autophagy induction and NLRP3 downregulation in models of spinal cord injury, brain ischemia, and LPS-treated primary spinal neurons [67,93].

It is remarkable that while acting as autophagy inducers, several phytochemicals are reported to act as proteasome-inhibitors, mainly through attenuation of chymotrypsin-like activity, as thoroughly reviewed in a recent paper [9]. However, as the proteasome activity probe assay is unable to discriminate between the activities of the various proteasome subunits, it cannot be ruled out that the observed changes in proteasome activity may stem from the β5i subunit of the immunoproteasome, which is strongly recruited to compensate for the inhibition of standard proteasome and autophagy. This is documented for resveratrol, the anti-inflammatory, and autophagy-inducing effects of which are associated with the downregulation of immunoproteasome [232,254]. In detail, resveratrol, through immunoproteasome inhibition, prevents immunoproteasome-dependent PTEN degradation to foster autophagy induction in vivo while inhibiting the expression of NF-kB, NLRP, and pro-inflammatory cytokines in vitro [232,254]. Resveratrol acts mainly through the downregulation of the LMP7 (B5i) immunoproteasome subunit which is responsible for its enhanced chymotrypsin-like activity [254].

In summary, the anti-inflammatory mechanisms of action of phytochemicals consist of mitigating neuroinflammatory pathways such as AGE/RAGEs, HMGB1/TLR-4, and NF-kB/NLRP3, and up-regulation of AMPK/SIRT1/PGC-1α and Nrf2, which are bound, at least in part, to rescuing autophagy and blunting immunoproteasome activities. Nonetheless, only a few studies focused on the direct relationship between phytochemicals and cell-clearing pathways, especially as it concerns the specific proteasome subtypes.

7. Conclusions

In the present review, we discussed experimental evidence merging the most common neuroprotective effects of different phytochemical classes in neurodegeneration and neuroinflammation (Table 2). A special emphasis was put on the role of cell clearing machinery and cell-to-cell communication mechanisms as a hub merging the antioxidant, mitochondrial protecting, anti-aggregation, and anti-inflammatory effects of phytochemicals. By targeting alterations of cell-clearing machinery, phytochemicals prevent the accumulation, and likely the propagation, of DAMPs, including oxidative and pro-inflammatory mediators and potentially toxic prionoids, and AGE-modified proteins. At the same time, the anti-inflammatory effects of some phytochemicals are bound to blunting the immunoproteasome, which may be key to rescuing neurons and glia from pro-inflammatory cytokine propagation and cytotoxic immune attack. However, this remains to be investigated and confirmed for most bioactive compounds beyond resveratrol. In summary, phytochemicals provide beneficial effects by downregulating oxidative and pro-inflammatory cascades such as AGE/RAGEs, JAK/STAT and mTOR, HMGB1/TLR-4 and NF-kB/NLRP3 while up-regulating AMPK/SIRT1/PGC-1α and Nrf2, which are bound, at least in part, to autophagy activation and blunting of immunoproteasome activity. The multi-faceted beneficial effects of phytochemicals may be a plus in the frame of neurodegeneration since a multi-target intervention appears more promising compared with precision medicine, which would implicate a tight correlation between specific proteins, pathogenic events, and single disorders.
Table 2. Summary of phytochemical-targeted molecular pathways in models of neurodegeneration, neurotoxicity and neuroinflammation.

| Phytochemical Experimental Model Polyphenols | Anti-Oxidant Effects | Mitochondrial Protection | Anti-Apoptotic Effects | Proteostasis | Anti-Inflammatory Effects | Autophagy-Related Effects |
|--------------------------------------------|----------------------|--------------------------|------------------------|--------------|---------------------------|--------------------------|
| Quercetin                                  | LDH ↓ROS ↑MDA ↑GSH  | ↑MMP ↓ultrastructural alterations [82,83] | ↓caspase-3 ↓BAX/Bcl-2 ↓CHOP ↓DNA fragmentation [51,158–161,247] | Aβ [51,211,222] α-syn [200] | ↓Reactive gliosis (GFAP) ↑IL-1β, IL-6, TNF-α [235,247] |
| Kaempferol                                 | ↓SDH ↑MDA ↑NRF2 ↑SOD ↑GSH ↑CAT [134,135] | ↑MMP ↑ATP ↓mitophagy ↓cyt-c [52,85] | ↓caspase-3/9 ↓JNK/p38MAPK | SOD-1 [84] Aβ [211] | ↓GFAP ↑NLRP3 ↓TNF-α, IL-1β |
| (Dihydro)-Myricetin                        | ↓ROS ↑MDA, LPO ↑NRF2 ↓SOD ↑GSH ↑CAT [134,135] | ↑MMP ↑ATP ↓mitophagy ↓cyt-c [134,135] | ↓caspase-3/9 ↓JNK/p38MAPK ↓BAX/Bcl-2 [86,134] | α-syn [54] PrP [209] Aβ [211] | ↓iNOS, COX-2, PGE2 ↓IL-1β, TNF-α [54,86] |
| Sutellarin                                 | ↓ROS ↑MDA, LPO ↑NRF2 ↓SOD ↑GSH [88,137] | ↑MMP [137] | ↓sub-G1 peak in flow cytometry [137] | Aβ [89,203] α-syn [203] | ↓NF-κB ↓IL-1β, TNF-α ↓IBA-1 microgliosis [88,89] |
| Baicalein                                  | ↓ROS [180] ↑mitophagy ↑MMP ↓fission [55,180] | ↓caspase-3/9/12 ↓BAX/Bcl-2 [55,56,87,180] | α-syn [87] | | ↓Microglial inflammomasome ↓IL-1β ↓IL-31 and IL-33 [97] |
| Apigenin                                   | ↑NRF2 ↑HO-1, NQO-1 ↑SOD, GSH-Px ↓ROS, MDA [61] | - | ↓ERK, STAT3 [90] | - | ↓Astrocyte activation ↓NF-κB |

Note: The table lists the phytochemicals and their effects in various experimental models of neurodegeneration, neurotoxicity, and neuroinflammation. The effects are summarized in terms of antioxidant activity, mitochondrial protection, anti-apoptotic effects, proteostasis, anti-inflammatory effects, and autophagy-related effects. The references for each effect are provided in the [ ] notation.
Table 2. Cont.

| Phytochemical | Experimental Model | Anti-Oxidant Effects | Mitochondrial Protection | Anti-Apoptotic Effects | Proteostasis | Anti-Inflammatory Effects | Autophagy-Related Effects |
|---------------|--------------------|-----------------------|--------------------------|------------------------|--------------|---------------------------|--------------------------|
| Catechins     | PD [50,255];       | ↓ROS                  | ↑mitophagy               | ↓BAX/Bcl-2             | α-syn        | ↑M2 microglia polarization| ↑LC3II ↓P62              |
|               | Prion [63];        |                       | ↓mitofragmentation       | ↓TUNEL                 | p-tau [91]   | ↑NLRP3 ↓NF-κB ↓IL-1β, TNF-α| ↑SIRT1 ↓mTOR              |
|               | AD [91];           |                       | ↓mtDNA copy number       | ↓cyt-c [63,182]        | Aβ [92,203,205,211,216] | ↓iNOS ↓COX-2 [256]      | ↑flux [50,63,92,182]      |
|               | Chronic stress [92]; |                       |                          |                        |              |                           |                          |
|               | Brain hemorrhage [182] |                       |                          |                        |              |                           |                          |
| Genistein     | Ischemia [93];     | ↓LDH, ROS [93,94]    | ↓BAX/Bcl-2              | ↓caspase-1/3/9         | -            | ↓NLRP3 in microglia and neurons| -                        |
|               | H$_2$O$_2$         |                       | ↓JNK, ERK [93,94]       | -                      |              |                           |                          |
|               | neurotoxicity [94] |                       |                          |                        |              |                           |                          |
| Silymarin/     | PD [95,96];        | ↑SOD, GSH-Px, CAT     | ↓BAX/Bcl-2              | APP and Aβ [257]       | -            | -                         | -                        |
| Silibinin     | AD [257]           | ↓MDA [95,96,257]      | ↓caspase-3/9            | -                      |              |                           |                          |
| Resveratrol   | PD [50,58,144];    | ↓ROS ↓MDA [58,59,65,97,99,144] | ↓mitofragmentation       | ↓TUNEL                 | polyQ-Htt [59] | ↑M2 microglia polarization| ↑ATG4 ↑LC3II ↓P62       |
|               | Chronic           |                       | ↑mitophagy               | ↓BAX/Bcl-2             | PrP [209]    | ↑P62 ↑PGC-1α ↑TLR-4/RAGE—| ↑flux ↓Akt/mTOR          |
|               | hypoperfusion [65];|                       | ↑Complex-I activity      | ↓caspase-3/9           | Aβ [213,214] | ↑NF-κB ↓HMGB1, NLRP3     | ↑SIRT1 [50,58,59,65,99–101] |
|               | LPS [69];          |                       |                         | ↓p38 and JNK [65,97,99,100] |              | ↓iNOS, COX-2 [69,101,102] |                          |
|               | Ischemia [97,101];|                       |                         |                         |              |                           |                          |
|               | AD [99,214];       |                       |                         |                         |              |                           |                          |
|               | Brain hemorrhage [100]; |                       |                         |                         |              |                           |                          |
|               | AGEs-induced       |                       |                         |                         |              |                           |                          |
|               | neuroinflammation [102] |                       |                         |                         |              |                           |                          |
| Syringic/gallic | Metabolic         | ↓ROS                  | -                        | ↓caspase-3 [105]       | α-syn        | ↓reactive gliosis (GFAP, ED-1)| -                        |
| acid         | syndrome [103];    |                       |                          |                        |              | ↓iNOS, IL-1β, TNF-α [103] |                          |
|               | LPS [104];         |                       |                          |                        |              |                           |                          |
|               | Deltamethrin       |                       |                          |                        |              |                           |                          |
|               | neurotoxicity [105]|                       |                          |                        |              |                           |                          |
Table 2. Cont.

| Phytochemicals | Experimental Model | Anti-Oxidant Effects | Mitochondrial Protection | Anti-Apoptotic Effects | Proteostasis | Anti-Inflammatory Effects | Autophagy-Related Effects |
|----------------|-------------------|----------------------|--------------------------|------------------------|-------------|--------------------------|--------------------------|
| Caffeic and chlorogenic acids | PD [62]; Spino cerebel lar ataxia [98]; Glutamate excitotoxicity [138]; AD [139]; Ischemia [140] | ↓ROS ↑NRF2 ↑SOD [98,138–140] | ↑MMP [138] | ↓caspase-9 [139] | α-syn [62] polyQ-ataxin3 [98] | ↓ Reactive gliosis (IGFAP, ED-1) ↓IL-2, TNF-α [139,140] | ↑JNK/Bcl-2 ↑LC3II ↓P62 [62,98] |
| Rosmarinic and Salvianolic acid | PD [54]; LPS [66]; Brain hemorrhage [141]; AD [172] | ↓ROS ↓MDA ↑SOD, GSH-Px, ↑GSH, CAT ↑NRF2 ↑HO-1, NQO-1 [141,172] | ↓fragmentation ↑MMP ↑ATP [172] | - | α-syn [54] Aβ [212] | ↓GFAP and IBA-1 ↓NLRP3 ↓IL-1β, IL-6, and TNF-α [54,66] | ↑LC3II ↑Bclin-1 ↑LAMP-1/2A [54,66] |
| Curcumin | PD [50,70,106,142,143,220,224]; SCI [57]; Ischemia [181]; AD [223]; Brain hemorrhage [245] | ↓ROS ↓MDA ↑SOD, GSH-Px, ↑NRF2 ↑GSH, CAT ↑ATP ↑mitophagy [70,106,142,143,224] | ↑MMP ↑ATP ↑mitophagy [70,181] | ↓BAX/Bcl-2 Caspase-3/9 α-syn [142,202,220,224] PrP [206–209] | APP and Aβ [106,223] | ↓Glosis ↓NOS ↓TNF-α, IL-1β, IL-1α ↓TLR4 | ↑LC3II ↓P62 ↓Akt/mTOR ↑TFEB [50,57,70,106,181,220,223] |
| Terpenes | Bacosides | ↓ROS ↑SOD, CAT ↑NRF2 [71,110,145] | ↓cyt-c ↑mitophagy ↑ATP ↑MMP [71,110,145] | ↓TUNEL, Annexin-V | ↑complex I–III and complex II–III activity ↓mitochondrial permeabilization [112,146] | - | - | ↑LC3II, Beclin-1, ATG5, ULK1 [71] |
| ALS [111]; PD [112]; Diabetes [146] | ↓ROS, LPO ↑GSH, SOD [112,146] | ↑complex I–III and complex II–III activity ↓mitochondrial permeabilization [112,146] | ↓NFKB | - | SOD-1 [111] | ↓Glosis (IGFAP and IBA-1) ↓NF-κB ↓COX-2 [111] | ↑LC3II ↓P62 [111] |
| Phytochemical Model | Anti-Oxidant Effects | Mitochondrial Protection | Anti-Apoptotic Effects | Proteostasis | Anti-Inflammatory Effects | Autophagy-Related Effects |
|---------------------|----------------------|--------------------------|------------------------|-------------|--------------------------|--------------------------|
| Carotenoids         | AMD [115]; AD [147]  | ↓ROS ↑GSH ↑NRF2 [115,147]| ↓mitochondrial uncoupling [147] | ↓JNK and ↓ER stress [115] | - - - | - - - |
| Alkaloids           | SCI [67]; AD [118,119]; ALS/FTD [120]; SBMA [121]; tert-butyl hydroperoxide neurotoxicity [148]; PD [149]; HD [225] | ↓ROS ↑NRF2—HO-1 [148,149] | ↑MMP [148] | ↓caspase-3 ↓BAX/Bcl-2 [67,148,149] | p-tau [118] Aβ, APP [119] TDP-43 [120] AR-<polyQ> polyQ-Htt [225] | ↓IL-1β, TNF-α [67] ↑LC3B, ATG16L, and ATG7 ↑P62 GSK3β ↓mTOR ↑PI3K/Bclin-1 [67,118,119] |
| Caffeine            | Prion [60]           | - - - | ↓JNK ↓DNA strand breakage [60] | PrP [60] | - | ↑LC3II ↑flux [60] |
| Other               | Spermine/ Spermidine | Prion [64]; PD [123]; Diabetes [124]; AD [215] | ↓ROS, LDH, MDA ↑NRF-2, GSH, NQO1, THx [64,123,124] | - | ↓TUNEL, Annexin-V ↓caspase-3 [64,123] PrP [64] AGE in retina [124] Aβ [215] | - | ↑LC3II ↓P62 ↑AMPK ↓mTOR [64,123] |

Table abbreviations: AD Alzheimer’s disease; AGE advanced glycation end products; ALS/FTD Amyotrophic Lateral Sclerosis/Frontotemporal dementia; APP amyloid precursor protein; AR-<polyQ> polyglutamine-expanded androgen receptor; CAT catalase; CHOP CCAAT-enhancer-binding protein homologous protein; COX-2 cyclooxygenase-2; Gfap glial fibrillary acid protein; GSH glutathione; GSH-Px GSH peroxidase; HO-1 heme oxygenase-1; IBA-1 ionized calcium-binding adapter molecule 1; iNOS inducible nitric oxide synthase; LDH lactate dehydrogenase; LPS lipopolysaccharide; MDA malondialdehyde; MMP mitochondrial membrane potential; NLRP3 inflammasome NLR family pyrin domain containing 3; NQO-1 NAD(P)H quinone oxidoreductase; NRF-2 Nuclear factor erythroid 2-related factor 2; PD Parkinson’s disease; PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGE2 prostaglandin E; polyQ-Htt polyglutamine expanded huntingtin; ROS Reactive Oxygen Species; SBMA Spinal Bulbar Muscular Atrophy; SCI spinal cord injury; SDH succinate dehydrogenase; SOD superoxide dismutase; TLR-4 toll-like receptor 4; THx thioredoxin.
This loosens the strength of the definition of precision medicine and opens new avenues to multi-target treatments in neurodegeneration. Despite the encouraging results on the beneficial effects of phytochemicals, experimental and clinical studies subjected to rigorous scientific scrutiny are needed to confirm whether these compounds may provide prophylactic or adjunct therapeutic support in neurodegeneration, potentially by acting as safe modulators of cell-clearing systems. In this frame, it is worth mentioning that concentration dependence weaves as well into the scheme of mechanistic complexity projected in the present review. The toxicity, effects, influence, and efficiency of action on behalf of phytochemicals (either individual or mixtures thereof) are parameters which, one way or another, relate to the concentration of the species projecting the biological activity. Although phytochemicals possess a relatively safe toxicity profile at doses that are generally required for neuroprotection, the abuse of phytochemicals is still a potential problem when no surveillance is carried out as for therapeutic compounds in general. Thus, although phytochemicals intake/administration may offer an advantageous prophylactic/adjunct health strategy due to a favorable risk–benefit profile, their usage and effects should be carefully considered and monitored.

**Author Contributions:** Conceptualization, F.F; writing—original draft preparation, F.L. and F.F.; writing—review, editing, F.L., F.B., F.M., M.P . and G.L.; artwork, F.L.; supervision, F.F.; funding acquisition, F.F. and F.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Ministero della Salute (Ricerca Corrente 2020).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Sharifi-Rad, M.; Lankatillake, C.; Dias, D.A.; Docea, A.O.; Mahomoodally, M.F.; Lobine, D.; Chazot, P.L.; Kurt, B.; Tumer, T.B.; Moreira, A.C.; et al. Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics. *J. Clin. Med*. 2020, 9, 1061. [CrossRef] [PubMed]

2. Pellegrini, C.; Fornai, M.; Antonioli, L.; Blandizzi, C.; Calderone, V. Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. *Int. J. Mol. Sci*. 2019, 20, 2876. [CrossRef] [PubMed]

3. Limanaqi, F.; Biagioni, F.; Busceti, C.L.; Ryskalin, L.; Polzella, M.; Frati, A.; Fornai, F. Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism. *Int. J. Mol. Sci*. 2019, 20, 3274. [CrossRef] [PubMed]

4. Bordoni, L.; Gabbianelli, R. Mitochondrial DNA and Neurodegeneration: Any Role for Dietary Antioxidants? *Antioxidants* 2020, 9, 764. [CrossRef] [PubMed]

5. Rajasekar, J.; Perumal, M.K.; Vallikannan, B. A critical review on anti-angiogenic property of phytochemicals. *J. Nutr. Biochem*. 2019, 71, 1–15. [CrossRef] [PubMed]

6. Abdullah, A.; Mohd Murshid, N.; Makpol, S. Antioxidant Modulation of mTOR and Sirtuin Pathways in Age-Related Neurodegenerative Diseases. *Mol. Neurobiol*. 2020. Epub ahead of print. [CrossRef]

7. Pinelli, R.; Biagioni, F.; Limanaqi, F.; Bertelli, M.; Scaffidi, E.; Polzella, M.; Busceti, C.L.; Fornai, F. A Re-Appraisal of Pathogenic Mechanisms Bridging Wet and Dry Age-Related Macular Degeneration Leads to Reconsider a Role for Phytochemicals. *Int. J. Mol. Sci*. 2020, 21, 5563. [CrossRef]

8. Rebas, E.; Rzajew, J.; Radzik, T.; Zylinska, L. Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways. *Curr. Neuropharmacol*. 2020, 18, 431–445. [CrossRef]

9. Mottaz, S.; Memariani, Z.; El-Senduny, F.F.; Sanadgol, N.; Golab, F.; Katebi, M.; Abdolghaffari, A.H.; Farzaei, M.H.; Abdollah, M. Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. *Front. Physiol*. 2020, 11, 361. [CrossRef]

10. Limanaqi, F.; Biagioni, F.; Gambardella, S.; Familiari, P.; Frati, A.; Fornai, F. Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies. *Int. J. Mol. Sci*. 2020, 21, 3028. [CrossRef]

11. Limanaqi, F.; Biagioni, F.; Ryskalin, L.; Busceti, C.L.; Fornai, F. Molecular Mechanisms Linking ALS/FTD and Psychiatric Disorders, the Potential Effects of Lithium. *Front. Cell. Neurosci*. 2019, 13, 450. [CrossRef] [PubMed]
12. Ryskalin, L.; Busceti, C.L.; Limanaqi, F.; Biagioni, F.; Gambardella, S.; Fornai, F. A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies. *Curr. Protein Pept. Sci.* **2018**, *19*, 598–611. [CrossRef]

13. Picca, A.; Calvani, R.; Coelho-Junior, H.J.; Landi, F.; Bernabei, R.; Marzetti, E. Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration. *Antioxidants* **2020**, *9*, 647. [CrossRef] [PubMed]

14. Giordano, S.; Darley-Usmar, V.; Zhang, J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. *Redox Biol.* **2013**, *2*, 82–90. [CrossRef] [PubMed]

15. Ahmad, S.; Khan, H.; Shahab, U.; Rehman, S.; Rafi, Z.; Khan, M.Y.; Ansari, A.; Siddiqui, Z.; Ashraf, J.M.; Abdullah, S.M.; et al. Protein oxidation: An overview of metabolism of sulphur containing amino acid, cysteine. *Front. Biosci. (Schol. Ed.)* **2017**, *9*, 71–87. [CrossRef] [PubMed]

16. Aman, Y.; Ryan, B.; Torsetnes, S.B.; Knapskog, A.B.; Watne, L.O.; McEwan, W.A.; Fang, E.F. Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases. *Int. Rev. Neurobiol.* **2020**, *155*, 169–202. [CrossRef]

17. Filomeni, G.; De Zio, D.; Cecconi, F. Oxidative stress and autophagy: The clash between damage and metabolic needs. *Cell Death Dis.* **2015**, *22*, 377–388. [CrossRef]

18. Limanaqi, F.; Biagioni, F.; Gaglione, A.; Busceti, C.L.; Fornai, F. A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome. *Front. Immunol.* **2019**, *10*, 628. [CrossRef]

19. Lazzeri, G.; Biagioni, F.; Fulceri, F.; Busceti, C.L.; Scavuzzo, M.C.; Ippolito, C.; Salvetti, A.; Lenzi, P.; Fornai, F. mTOR Modulates Methamphetamine-Induced Toxicity through Cell Clearing Systems. *Oxid. Med. Cell. Longev.* **2018**, *2018*, 6124745. [CrossRef]

20. Castino, R.; Lazzeri, G.; Lenzi, P.; Bellio, N.; Follro, C.; Ferrucci, M.; Fornai, F.; Isidoro, C. Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine. *J. Neurochem.* **2008**, *106*, 1426–1439. [CrossRef]

21. Limanaqi, F.; Biagioni, F.; Ryskalin, L.; Fornai, F. mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. *Int. J. Mol. Sci.* **2018**, *19*, 2226. [CrossRef] [PubMed]

22. Sato, S.; Uchihara, T.; Fukuda, T.; Noda, S.; Kondo, H.; Saiki, S.; Komatsu, M.; Uchiyama, Y.; Tanaka, K.; Hattori, N. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice. *Sci. Rep.* **2018**, *8*, 2813. [CrossRef] [PubMed]

23. Limanaqi, F.; Biagioni, F.; Gambardella, S.; Ryskalin, L.; Fornai, F. The effects of proteasome on baseline and methamphetamine-dependent dopamine transmission. *Neurosci. Biobehav. Rev.* **2019**, *102*, 308–317. [CrossRef] [PubMed]

24. Limanaqi, F.; Biagioni, F.; Gambardella, S.; Ryskalin, L.; Fornai, F. Interdependency between Autophagy and Synaptic Vesicle Trafficking: Implications for Dopamine Release. *Front. Mol. Neurosci.* **2018**, *11*, 299. [CrossRef]

25. Limanaqi, F.; Busceti, C.L.; Biagioni, F.; Cantini, F.; Lenzì, P.; Fornai, F. Cell-Clearing Systems Bridging Repeat Expansion Proteotoxicity and Neuromuscular Junction Alterations in ALS and SBMA. *Int. J. Mol. Sci.* **2020**, *21*, 4021. [CrossRef]

26. Song, J.X.; Lu, J.H.; Liu, L.F.; Chen, L.L.; Durairajan, S.S.; Yue, Z.; Zhang, H.Q.; Li, M. HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: A process modulated by the natural autophagy inducer corynoxine B. *Autophagy* **2014**, *10*, 144–154. [CrossRef]

27. Thibaudeau, T.A.; Anderson, R.T.; Smith, D.M. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. *Nat. Commun.* **2018**, *9*, 1097. [CrossRef]

28. Lai, M.; Yao, H.; Shah, S.Z.A.; Wu, W.; Wang, D.; Zhao, Y.; Wang, L.; Zhou, X.; Zhao, D.; Yang, L. The NLRP3-Caspase 1 Inflammasome Negatively Regulates Autophagy via TLR4-TRIF in Prion Peptide-Infected Microglia. *Front. Aging Neurosci.* **2018**, *10*, 116. [CrossRef]

29. Wang, Y.; Meng, C.; Zhang, J.; Wu, J.; Zhao, J. Inhibition of GSK-3β alleviates cerebral ischemia/reperfusion injury in rats by suppressing NLRP3 inflammasome activation through autophagy. *Int. Immunopharmacol.* **2019**, *68*, 234–241. [CrossRef]

30. Lázaro, D.F.; Bellucci, A.; Brundin, P.; Outeiro, T.F. Editorial: Protein Misfolding and Spreading Pathology in Neurodegenerative Diseases. *Front. Mol. Neurosci.* **2020**, *12*, 312. [CrossRef]
31. Maurel, C.; Dangoumau, A.; Marouillat, S.; Brulard, C.; Chami, A.; Hergesheimer, R.; Corcia, P.; Blasco, H.; Andres, C.R.; Vourc'h, P. Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: A Link to Neurodegeneration. *Mol. Neurobiol.* 2018, 55, 6480–6499. [CrossRef] [PubMed]

32. Ferrucci, M.; Biagioni, F.; Ryskalin, L.; Limanaqi, F.; Gambardella, S.; Frati, A.; Fornai, F. Ambiguous Effects of Autophagy Activation Following Hypoperfusion/Ischemia. *Int. J. Mol. Sci.* 2018, 19, 2756. [CrossRef]

33. Cortes, C.J.; Miranda, H.C.; Frankowski, H.; Batlevi, Y.; Young, J.E.; Le, A.; Ivanov, N.; Sopher, B.L.; Carromeu, C.; Muotri, A.R.; et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. *Nat. Neurosci.* 2014, 17, 1180–1189. [CrossRef]

34. Rusmini, P.; Cortese, K.; Crippa, V.; Lazzeri, G.; Falleni, A.; Biagioni, F.; Ryskalin, L.; Fornai, F. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. *Autophagy* 2019, 15, 631–651. [CrossRef] [PubMed]

35. Natale, G.; Lenzi, P.; Lazzeri, G.; Falleni, A.; Biagioni, F.; Ryskalin, L.; Fornai, F. Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases. *Eur. J. Histochem.* 2013, 57, e5. [CrossRef]

36. Li, J.; Liu, D.; Sun, L.; Lu, Y.; Zhang, Z. Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. *Neuron* 2009, 64, 783–790. [CrossRef] [PubMed]

37. Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. *Redox Biol.* 2014, 2, 411–429. [CrossRef]

38. Grimm, S.; Ernst, L.; Grotzinger, N.; Hohn, A.; Breusing, N.; Reinheckel, T.; Grune, T. Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. *Free Radic. Res.* 2010, 44, 1013–1026. [CrossRef] [PubMed]

39. Grimm, S.; Ott, C.; Hörlacher, M.; Weber, D.; Höhn, A.; Grune, T. Advanced-glycation-end-product-induced formation of immunoproteasomes: Involvement of RAGE and Jak2/STAT1. *Biochem. J.* 2012, 448, 127–139. [CrossRef] [PubMed]

40. Pla, A.; Pascual, M.; Renau-Piqueras, J.; Guerri, C. TLR4 mediates the impairment of ubiquitin-proteasome and autophagy-lysosome pathways induced by ethanol treatment in brain. *Cell Death Dis.* 2014, 5, e1066. [CrossRef] [PubMed]

41. Zhang, S.; Hu, L.; Jiang, J.; Li, H.; Wu, Q.; Ooi, K.; Wang, J.; Feng, Y.; Zhu, D.; Xia, C. HMGB1/RAGE axis mediates stress-induced RVLM neuroinflammation in mice via impairing mitophagy flux in microglia. *J. Neuroinflamm.* 2020, 17, 15. [CrossRef]

42. Ray, R.; Juranek, J.K.; Rai, V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. *Neurosci. Biobehav. Rev.* 2016, 62, 48–55. [CrossRef] [PubMed]

43. Pietrocasa, F.; Mariño, G.; Lissa, D.; Vacchelli, E.; Malik, S.A.; Niso-Santano, M.; Zamzami, N.; Galluzzi, L.; Maiuri, M.C.; Kroemer, G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. *Cell Cycle* 2012, 11, 3851–3860. [CrossRef]
50. Li, P.; Ma, K.; Wu, H.Y.; Wu, Y.P.; Li, B.X. Isoflavones Induce BEX2-Dependent Autophagy to Prevent ATR-Induced Neurotoxicity in SH-SY5Y Cells. Cell Physiol. Biochem. 2017, 43, 1866–1879. [CrossRef]

51. Liu, Y.; Zhou, H.; Yin, T.; Gong, Y.; Yuan, G.; Chen, L.; Liu, J. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease. J. Colloid. Interface Sci. 2019, 552, 388–400. [CrossRef] [PubMed]

52. Filomeni, G.; Graziani, I.; De Zio, D.; Dini, L.; Centonze, D.; Rotilio, G.; Cirio, M.R. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: Possible implications for Parkinson’s disease. Neurobiol. Aging. 2013, 33, 767–785. [CrossRef] [PubMed]

53. Han, X.; Sun, S.; Sun, Y.; Song, Q.; Zhu, J.; Song, N.; Chen, M.; Sun, T.; Xia, M.; Ding, J.; et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: Implications for Parkinson disease. Autophagy 2019, 15, 1860–1881. [CrossRef] [PubMed]

54. Wu, J.Z.; Ardal, M.; Haikal, C.; Svanbergsson, A.; Diepenbroek, M.; Vaikath, N.N.; Li, W.; Wang, Z.Y.; Outeiro, T.F.; El-Agnaf, O.M.; et al. Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Transl. Neurodegener. 2019, 8, 18. [CrossRef]

55. Kuang, L.; Cao, X.; Lu, Z. Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy. Biol. Pharm. Bull. 2017, 40, 1537–1543. [CrossRef]

56. Li, Y.; Lin, S.; Xu, C.; Zhang, P.; Mei, X. Triggering of Autophagy by Baicalein in Response to Apoptosis Spinal Cord Injury. Oncotarget 2019, 10, 8674–8684. [CrossRef] [PubMed]

57. Li, W.; Yao, S.; Li, H.; Meng, Z.; Sun, X. Curcumin promotes functional recovery and inhibits neuronal apoptosis after spinal cord injury through the modulation of autophagy. J. Spinal Cord Med. 2019, 1–9, Epub ahead of print. [CrossRef]

58. Lin, K.L.; Lin, K.J.; Wang, P.W.; Chuang, J.H.; Lin, H.Y.; Chen, S.D.; Chuang, Y.C.; Huang, S.T.; Tiao, M.M.; et al. Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Free Radic. Res. 2018, 52, 1371–1386. [CrossRef]

59. Vidoni, C.; Secomandi, E.; Castiglioni, A.; Melone, M.A.B.; Isidoro, C. Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation. Neurochem. Int. 2018, 117, 174–187. [CrossRef]

60. Moon, J.H.; Lee, J.H.; Park, J.Y.; Kim, S.W.; Lee, Y.J.; Kang, S.J.; Seol, J.W.; Ahn, D.C.; Park, S.Y. Caffeine prevents human prion protein-mediated neurotoxicity through the induction of autophagy. Int. J. Mol. Med. 2014, 34, 553–558. [CrossRef]

61. Zhang, Y.; Yang, Y.; Yu, H.; Li, M.; Hang, L.; Xu, X. Apigenin Protects Mouse Retina against Oxidative Damage by Regulating the Nrf2 Pathway and Autophagy. Oxid. Med. Cell. Longev. 2020, 2020, 9420704. [CrossRef] [PubMed]

62. Zhang, Y.; Wu, Q.; Zhang, L.; Wang, Q.; Yang, Z.; Liu, J.; Feng, L. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson’s disease. Pharmacol. Res. 2019, 150, 104538. [CrossRef] [PubMed]

63. Lee, J.H.; Moon, J.H.; Kim, S.W.; Jeong, J.K.; Nazim, U.M.; Lee, Y.J.; Seol, J.W.; Park, S.Y. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells. Oncotarget 2015, 6, 9701–9717. [CrossRef] [PubMed]

64. Lee, J.H.; Jeong, J.K.; Park, S.Y. Sulforaphane-induced autophagy flux prevents prion protein-mediated neurotoxicity through AMPK pathway. Neuroscience 2014, 278, 31–39. [CrossRef]

65. Wang, N.; He, J.; Pan, C.; Wang, J.; Ma, M.; Shi, X.; Xu, Z. Resveratrol Activates Autophagy via the AKT/mTOR Signaling Pathway to Improve Cognitive Dysfunction in Rats With Chronic Cerebral Hypoperfusion. Front. Neurosci. 2019, 13, 859. [CrossRef]

66. Jiang, P.; Guo, Y.; Deng, R.; Yang, M.; Liao, D.; Li, H.; Sun, Z.; Feng, Q.; Xu, P. Salvianolic acid B protects against lipopolysaccharide-induced behavioral deficits and neuroinflammatory response: Involvement of autophagy and NLRP3 inflammasome. J. Neuroinflamm. 2017, 14, 239. [CrossRef]

67. Wang, H.; Liu, C.; Mei, X.; Cao, Y.; Guo, Z.; Yuan, Y.; Zhao, Z.; Song, C.; Guo, Y.; Shen, Z. Berberine attenuated pro-inflammatory factors and protect against neuronal damage via triggering oligodendrocyte autophagy in spinal cord injury. Oncotarget 2017, 8, 98312–98321. [CrossRef]

68. Sigrist, S.J.; Carmona-Gutierrez, D.; Gupta, V.K.; Bhukel, A.; Mertel, S.; Eisenberg, T.; Madeo, F. Spermidine-triggered autophagy ameliorates memory during aging. Autophagy 2014, 10, 178–179. [CrossRef]
69. Yang, X.; Xu, S.; Qian, Y.; Xiao, Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury. *Brain Behav. Immun.* 2017, 64, 162–172. [CrossRef]

70. Zhuang, X.X.; Wang, S.F.; Tan, Y.; Song, J.X.; Zhu, Z.; Wang, Z.Y.; Wu, M.Y.; Cai, C.Z.; Huang, Z.J.; Tan, J.Q.; et al. Pharmacological enhancement of TFEB-mediated autophagy alleviated neuronal death in oxidative stress-induced Parkinson’s disease models. *Cell Death Dis.* 2020, 11, 128. [CrossRef]

71. Saha, S.; Mahapatra, K.K.; Mishra, S.R.; Mallick, S.; Negi, V.D.; Sarangi, I.; Patil, S.; Patra, S.K.; Bhutia, S.K. Bacopa monnieri inhibits apoptosis and senescence through mitophagy in human astrocytes. *Food Chem. Toxicol.* 2020, 141, 111367. [CrossRef] [PubMed]

72. Liu, R.H. Potential synergy of phytochemicals in cancer prevention: Mechanism of action. *J. Nutr.* 2004, 134, 3479S–3485S. [CrossRef] [PubMed]

73. Campos-Vega, R.; Oomah, B.D. Chemistry and classification of phytochemicals. In *Handbook of Plant Food Phytochemicals*; Tiwari, B., Brunton, N.P., Brennan, C.S., Eds.; John Wiley & Sons: Hoboken, NJ, USA, 2013.

74. Joseph, J.; Cole, G.; Head, E.; Ingram, D. Nutrition, brain aging, and neurodegeneration. *J. Neurosci.* 2009, 29, 12795–12801. [CrossRef]

75. Potì, F.; Santi, D.; Spaggiari, G.; Zimetti, F.; Zanotti, I. Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis. *Int. J. Mol. Sci.* 2019, 20, 351. [CrossRef] [PubMed]

76. Suganthy, N.; Devi, K.P.; Nabavi, S.F.; Braidy, N.; Nabavi, S.M. Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. *Biomed Pharmacother.* 2016, 84, 892–908. [CrossRef]

77. Costa, L.G.; Garrick, J.M.; Roqué, P.J.; Pellacani, C. Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More. *Oxid. Med. Cell. Longev.* 2016, 2016, 2986796. [CrossRef]

78. Huang, Y.; Chen, Y.; Shaw, A.M.; Goldfine, H.; Tian, J.; Cai, J. Enhancing TFEB-Mediated Cellular Degradation Pathways by the mTORC1 Inhibitor Quercetin. *Oxid. Med. Cell. Longev.* 2018, 2018, 5073420. [CrossRef]

79. Ip, P.; Sharda, P.R.; Cunningham, A.; Chakrabartty, S.; Pande, V.; Chakrabartty, A. Quercitrin and quercetin 3-β-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant. *Protein Eng. Des. Sel.* 2017, 30, 431–440. [CrossRef]

80. Pakrashi, S.; Chakraborty, J.; Bandyopadhyay, J. Neuroprotective Role of Quercetin on Rotenone-Induced Toxicity in SH-SY5Y Cell Line through Modulation of Apoptotic and Autophagic Pathways. *Neurochem. Res.* 2020, 45, 1962–1973. [CrossRef] [PubMed]

81. Ueda, T.; Inden, M.; Shirai, K.; Sekine, S.I.; Masaki, Y.; Kurita, H.; Ichihara, K.; Inuzuka, T.; Hozumi, I. The effects of Brazilian green propolis that contains flavonols against mutant copper-zinc superoxide dismutase-mediated toxicity. *Sci. Rep.* 2017, 7, 2882. [CrossRef]

82. Jang, J.H.; Lee, S.H.; Jung, K.; Yoo, H.; Park, G. Inhibitory Effects of Myricetin on Lipopolysaccharide-Induced Neuroinflammation. *Brain Sci.* 2020, 10, 32. [CrossRef]

83. Hung, K.C.; Huang, H.J.; Wang, Y.T.; Lin, A.M. Baicalein attenuates α-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo. *J. Ethnopharmacol.* 2016, 194, 522–529. [CrossRef]
88. Baluchnejadmoghadam, T.; Zeinali, H.; Roghani, M. Scutellarin alleviates lipopolysaccharide-induced cognitive deficits in the rat: Insights into underlying mechanisms. *Int. Immunopharmacol.* 2018, 54, 311–319. [CrossRef]

89. Che, D.N.; Cho, B.O.; Kim, J.S.; Shin, J.Y.; Kang, H.J.; Jang, S.I. Luteolin and Apigenin Attenuate LPS-Induced Astrocyte Activation and Cytokine Production by Targeting MAPK, STAT3, and NF-kB Signaling Pathways. *Inflammation* 2020, 43, 1716–1728. [CrossRef]

90. Che, D.N.; Cho, B.O.; Kim, J.S.; Shin, J.Y.; Kang, H.J.; Jang, S.I. Luteolin and Apigenin Attenuate LPS-Induced Astrocyte Activation and Cytokine Production by Targeting MAPK, STAT3, and NF-κB Signaling Pathways. *Inflammation* 2020, 43, 1716–1728. [CrossRef]

91. Chesser, A.S.; Ganeshan, V.; Yang, J.; Johnson, G.V. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. *Nutr. Neurosci.* 2016, 19, 21–31. [CrossRef]

92. Che, D.N.; Cho, B.O.; Kim, J.S.; Shin, J.Y.; Kang, H.J.; Jang, S.I. Luteolin and Apigenin Attenuate LPS-Induced Astrocyte Activation and Cytokine Production by Targeting MAPK, STAT3, and NF-κB Signaling Pathways. *Inflammation* 2020, 43, 1716–1728. [CrossRef]

93. Chesser, A.S.; Ganeshan, V.; Yang, J.; Johnson, G.V. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. *Nutr. Neurosci.* 2016, 19, 21–31. [CrossRef]

94. Gu, H.F.; Nie, Y.X.; Tong, Q.; Tang, Y.L.; Zeng, Y.; Jing, K.Q.; Zheng, X.L.; Liao, D.F. Epigallocatechin-3-gallate attenuates oxidative stress and apoptosis in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment. *Nanomedicine* 2020, 25, 309–317. [CrossRef]

95. Haddadi, R.; Nayebi, A.M.; Eyvari-Brooshghalan, S. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. *Biomed Pharmacother.* 2018, 104, 127–136. [CrossRef]

96. Haddadi, R.; Eyvari-Brooshghalan, S.; Nayebi, A.M.; Sabahi, M.; Ahmadi, S.A. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment. *Nanomedicine* 2020, 25, 309–317. [CrossRef]

97. Haddadi, R.; Nayebi, A.M.; Eyvari-Brooshghalan, S. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. *Biomed Pharmacother.* 2018, 104, 127–136. [CrossRef]

98. Haddadi, R.; Eyvari-Brooshghalan, S.; Nayebi, A.M.; Sabahi, M.; Ahmadi, S.A. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment. *Nanomedicine* 2020, 25, 309–317. [CrossRef]

99. Haddadi, R.; Eyvari-Brooshghalan, S.; Nayebi, A.M.; Sabahi, M.; Ahmadi, S.A. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment. *Nanomedicine* 2020, 25, 309–317. [CrossRef]

100. Gu, H.; Xie, J.; Zhao, J.; Huang, T.; Guo, X.; Song, J. Resveratrol protects early brain injury after subarachnoid hemorrhage by activating autophagy and inhibiting apoptosis mediated by the Akt/mTOR pathway. *Neuroreport* 2018, 29, 368–379. [CrossRef]

101. Gu, H.; Xie, J.; Zhao, J.; Huang, T.; Guo, X.; Song, J. Resveratrol protects early brain injury after subarachnoid hemorrhage by activating autophagy and inhibiting apoptosis mediated by the Akt/mTOR pathway. *Neuroreport* 2018, 29, 368–379. [CrossRef]

102. Gu, H.; Xie, J.; Zhao, J.; Huang, T.; Guo, X.; Song, J. Resveratrol protects early brain injury after subarachnoid hemorrhage by activating autophagy and inhibiting apoptosis mediated by the Akt/mTOR pathway. *Neuroreport* 2018, 29, 368–379. [CrossRef]

103. Haddadi, R.; Nayebi, A.M.; Eyvari-Brooshghalan, S. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. *Biomed Pharmacother.* 2018, 104, 127–136. [CrossRef]

104. Haddadi, R.; Nayebi, A.M.; Sabahi, M.; Ahmadi, S.A. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment. *Nanomedicine* 2020, 25, 309–317. [CrossRef]
106. Jaroonwitchawan, T.; Chaicharoenudomrung, N.; Namkaew, J.; Noisa, P. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. *Neurosci Lett.* 2017, 636, 40–47. [CrossRef] [PubMed]

107. Abrahams, S.; Haylett, W.L.; Johnson, G.; Carr, J.A.; Bardien, S. Antioxidant effects of curcumin in models of neurodegeneration, aging, oxidative and nitrosative stress: A review. *Neuroscience* 2019, 406, 1–21. [CrossRef]

108. Bohlmann, J.; Keeling, C.I. Terpenoid biomaterials. *Plant J.* 2008, 54, 656–669. [CrossRef]

109. Aguiar, S.; Borowski, T. Neuropharmacological review of the nootropic herb *Bacopa monnieri*. *Rejuvenation Res.* 2013, 16, 313–326. [CrossRef]

110. Srivastav, S.; Fatima, M.; Mondal, A.C. *Bacopa monnieri* alleviates paraquat induced toxicity in Drosophila by inhibiting jnk mediated apoptosis through improved mitochondrial function and redox stabilization. *Neurochem Int.* 2018, 121, 98–107. [CrossRef]

111. Wadhwa, R.; Konar, A.; Kauf, S.C. Nootropic potential of Ashwagandha leaves: Beyond traditional root extracts. *Neurochem. Int.* 2016, 95, 109–118. [CrossRef]

112. Dutta, K.; Patel, P.; Julien, J.P. Protective effects of *Withania somnifera* extract in SOD1G93A mouse model of amyotrophic lateral sclerosis. *Exp. Neurol.* 2018, 309, 193–204. [CrossRef] [PubMed]

113. Manjunath, M.J.; Muralidhara. Standardized extract of *Withania somnifera* (Ashwagandha) markedly offsets rotenone-induced locomotor deficits, oxidative impairments and neurotoxicity in *Drosophila melanogaster*. *J. Food Sci. Technol.* 2015, 52, 1971–1981. [CrossRef] [PubMed]

114. Cho, K.S.; Shin, M.; Kim, S.; Lee, S.B. Recent Advances in Studies on the Therapeutic Potential of Dietary Carotenoids in Neurodegenerative Diseases. *Oxid. Med. Cell. Longev.* 2018, 2018, 4120458. [CrossRef] [PubMed]

115. Yu, M.; Yan, W.; Beight, C. Lutein and Zeaxanthin Isomers Protect against Light-Induced Retinopathy via Decreasing Oxidative and Endoplasmic Reticulum Stress in BALB/cj Mice. *Nutrients* 2018, 10, 842. [CrossRef] [PubMed]

116. Hussain, G.; Rasul, A.; Anwar, H.; Aziz, N.; Razzaq, A.; Wei, W.; Ali, M.; Li, J.; Li, X. Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders. *Int. J. Biol. Sci.* 2018, 14, 341–357. [CrossRef]

117. Qin, S.; Tang, H.; Li, W.; Gong, Y.; Li, S.; Huang, J.; Fang, Y.; Yuan, W.; Liu, Y.; Wang, S.; et al. AMPK and its activator Berberine in the Treatment of Neurodegenerative Diseases. *Curr. Pharm. Des.* 2020. Epub ahead of print. [CrossRef]

118. Chen, Y.; Chen, Y.; Liang, Y.; Chen, H.; Ji, X.; Huang, M. Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. *Biomed. Pharmacother.* 2020, 121, 109670. [CrossRef]

119. Huang, M.; Jiang, X.; Liang, Y.; Liu, Q.; Chen, S.; Guo, Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer’s disease. *Exp. Gerontol.* 2017, 91, 25–33. [CrossRef]

120. Chang, C.F.; Lee, Y.C.; Lee, K.H.; Lin, H.C.; Chen, C.L.; Shen, C.J.; Huang, C.C. Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS. *J. Biomed. Sci.* 2016, 23, 72. [CrossRef]

121. Rusmini, P.; Cristofani, R.; Tedesco, B.; Ferrari, V.; Messi, E.; Piccolella, M.; Casarotto, E.; Chierichetti, M.; Cicardi, M.E.; Galbiati, M.; et al. Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives. *Int. J. Mol. Sci.* 2020, 21, 3443. [CrossRef]

122. Santín-Márquez, R.; Alarcon-Aguilar, A.; López-Diazguerrero, N.E.; Chondrogianni, N.; Königsberg, M. Sulforaphane—Role in aging and neurodegeneration. *Geroscience* 2019, 41, 655–670. [CrossRef]

123. Zhou, Q.; Chen, B.; Wang, X.; Wu, L.; Yang, Y.; Cheng, X.; Hu, Z.; Cai, X.; Yang, J.; Sun, X.; et al. Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways. *Sci. Rep.* 2016, 6, 32206. [CrossRef]

124. Ren, X.; Wang, N.N.; Qi, H.; Qiu, Y.Y.; Zhang, C.H.; Brown, E.; Kong, H.; Kong, L. Up-Regulation of Thioredoxin Inhibits Advanced Glycation End Products-Induced Neurodegeneration. *Cell. Physiol. Biochem.* 2018, 50, 1673–1686. [CrossRef]

125. Yang, Y.; Chen, S.; Zhang, Y.; Lin, X.; Song, Y.; Xue, Z.; Qian, H.; Wang, S.; Wan, G.; Zheng, X.; et al. Induction of autophagy by spermidine is neuroprotective via inhibition of caspase 3-mediated Beclin 1 cleavage. *Cell Death Dis.* 2017, 8, e2738. [CrossRef]
126. Vijayan, B.; Raj, V.; Nandakumar, S.; Kishore, A.; Thekkuveettil, A. Spermine protects alpha-synuclein expressing dopaminergic neurons from manganese-induced degeneration. *Cell. Biol. Toxicol.* 2019, 35, 147–159. [CrossRef] [PubMed]

127. Ghosh, I.; Sankhe, R.; Mudgal, J.; Arora, D.; Namboothiri, M. Spermidine, an autophagy inducer, as a therapeutic strategy in neurological disorders. *Neurotoxics* 2020, 102083. [CrossRef] [PubMed]

128. Limanaqi, F.; Gambardella, S.; Biagioni, F.; Busceti, C.L.; Fornai, F. Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress. *Oxid. Med. Cell. Longev.* 2018, 2018, 4982453. [CrossRef] [PubMed]

129. Cobley, J.N.; Fiorello, M.L.; Bailey, D.M. 13 reasons why the brain is susceptible to oxidative stress. *Relax Biol.* 2018, 15, 490–503. [CrossRef] [PubMed]

130. Said Ahmed, M.; Hung, W.Y.; Zu, J.S.; Hockberger, P.; Siddique, T. Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. *J. Neurol. Sci.* 2000, 176, 88–94. [CrossRef]

131. Arredondo, F.; Echeverry, C.; Abin-Carriquiry, J.A.; Blasina, F.; Antuñez, K.; Jones, D.P.; Go, Y.M.; Liang, Y.L.; Dajas, F. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult. *Free Radic. Biol. Med.* 2010, 49, 738–747. [CrossRef]

132. Wang, J.; Mao, J.; Wang, R.; Li, S.; Wu, B.; Yuan, Y. Kaempferol Protects Against Cerebral Ischemia Reperfusion Injury Through Intervening Oxidative and Inflammatory Stress Induced Apoptosis. *Front. Pharmacol.* 2020, 11, 424. [CrossRef] [PubMed]

133. Hussein, R.M.; Mohamed, W.R.; Omar, H.A. A neuroprotective role of kaempferol against chlorpyrifos-induced oxidative stress and memory deficits in rats via GSK3β-Nrf2 signaling pathway. *Pestic. Biochem. Physiol.* 2018, 152, 29–37. [CrossRef] [PubMed]

134. Dhanraj, V.; Karuppaiah, J.; Balakrishnan, R.; Elangovan, N. Myricetin attenuates neurodegeneration and cognitive impairment in Parkinsonism. *Front. Biosci (Elite Ed.)* 2018, 10, 481–494. [CrossRef]

135. Wu, S.; Yue, Y.; Peng, A.; Zhang, L.; Xiong, J.; Cao, X.; Ding, H.; Yin, S. Myricetin ameliorates brain injury and neurological deficits via Nrf2 activation after experimental stroke in middle-aged rats. *Front. Behav. Neurosci.* 2016, 7, 2624–2634. [CrossRef]

136. Choi, S.M.; Kim, B.C.; Cho, Y.H.; Choi, K.H.; Chang, J.; Park, M.S.; Kim, M.K.; Cho, K.H.; Kim, J.K. Effects of Flavonoid Compounds on β-amyloid-peptide-induced Neuronal Death in Cultured Mouse Cortical Neurons. *Chonnam. Med. J.* 2014, 50, 45–51. [CrossRef] [PubMed]

137. Hong, H.; Liu, G.Q. Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. *Life Sci.* 2004, 74, 2959–2973. [CrossRef]

138. Chao, X.J.; Chen, Z.W.; Liu, A.M.; He, X.X.; Wang, S.G.; Wang, Y.T.; Liu, P.Q.; Ramassamy, C.; Mak, S.H.; Cui, W.; et al. Effect of tarecine-3-cafeic acid, a novel multifunctional anti-Alzheimer’s dimer, against oxidative-stress-induced cell death in HT22 hippocampal neurons: Involvement of Nrf2/HO-1 pathway. *CNS Neurosci. Ther.* 2014, 20, 840–850. [CrossRef] [PubMed]

139. Dhanraj, V.; Karuppaiah, J.; Balakrishnan, R.; Elangovan, N. Myricetin attenuates oxidative stress induced apoptosis in MPTP induced parkinsonian mice. *Naunyn. Schmiedebergs Arch. Pharmacol.* 2018, 1022 27 of 34.

140. Lee, T.K.; Kang, I.J.; Kim, B.; Sim, H.J.; Kim, M.K.; Cho, K.H.; Kim, J.K. Effects of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson’s disease. *Neurosci. Schmiedebergs Arch. Pharmacol.* 2018, 391, 445–453. [CrossRef] [PubMed]
145. Bhardwaj, P.; Jain, C.K.; Mathur, A. Comparative evaluation of four triterpenoid glycoside saponins of bacoside A in alleviating sub-cellular oxidative stress of N2a neuroblastoma cells. *J. Pharm. Pharmacol.* 2018, 70, 1531–1540. [CrossRef] [PubMed]

146. Parihar, P.; Shetty, R.; Ghafoorifar, P.; Parihar, M.S. Increase in oxidative stress and mitochondrial impairment in hypothalamus of streptozotocin treated diabetic rat: Antioxidative effect of Withania somnifera. *Cell. Mol. Biol. (Noisy-le-grand)*. 2016, 62, 73–83.

147. Ademowo, O.S.; Dias, I.H.K.; Diaz-Sanchez, L.; Sanchez-Aranguren, L.; Stahl, W.; Griffiths, H.R. Partial Mitigation of Oxidized Phospholipid-Mediated Mitochondrial Dysfunction in Neuronal Cells by Oxocarotenoids. *J. Alzheimers Dis.* 2020, 74, 113–126. [CrossRef] [PubMed]

148. Chen, C.; Li, C.; Chen, S.; Li, Z.; Jia, X.; Wang, K.; Bao, J.; Liang, Y.; Wang, X.; Chen, M.; et al. Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways. *Redox Biol.* 2017, 11, 1–11. [CrossRef]

150. Sharma, S.; Kumar, P.; Deshmukh, R. Neuroprotective potential of spermidine against rotenone induced Parkinson’s disease in rats. *Neurochem. Int.* 2018, 116, 104–111. [CrossRef]

153. Minakaki, G.; Menges, S.; Kittel, A.; Emmanouilidou, E.; Schae

154. Menon, M.B.; Dhamija, S. Beclin 1 Phosphorylation - at the Center of Autophagy Regulation. *Oncotarget* 2016, 7, 83833–83834. [CrossRef] [PubMed]

155. Minakaki, G.; Menges, S.; Kittel, A.; Emmanouilidou, E.; Schaeffner, I.; Barkovits, K.; Bergmann, A.; Rockenstein, E.; Adame, A.; Marxreiter, F.; et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. *Autophagy* 2018, 14, 98–119. [CrossRef] [PubMed]

156. Zhou, J.; Tan, S.H.; Nicolas, V.; Bauvy, C.; Yang, N.D.; Zhang, J.; Xue, Y.; Codogno, P.; Shen, H.M. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. *Cell Res.* 2013, 23, 508–523. [CrossRef]

157. Lenz, P.; Lazzari, G.; Biagioni, F.; Busceti, C.L.; Gambardella, S.; Salvetti, A.; Fornai, F. The Autophagophagosome as a Novel Cell Clearing Organelle in Baseline and Stimulated Conditions. *Front. Neuroanat.* 2016, 10, 78. [CrossRef]

158. Wan, F.Y.; Wang, Y.N.; Zhang, G.J. The influence of oxidation of membrane thiol groups on lysosomal proton permeability. *Biochem. J.* 2001, 365, 355–362. [CrossRef]

159. Dodson, M.; Wani, W.Y.; Redmann, M.; Benavides, G.A.; Johnson, M.S.; Ouyang, X.; Cofield, S.S.; Mitra, K.; Darley-Usmar, V.; Zhang, J. Regulation of autophagy, mitochondrial dynamics, and cellular bioenergetics by 4-hydroxynonenal in primary neurons. *Autophagy* 2017, 13, 1828–1840. [CrossRef]

160. Janda, E.; Lascala, A.; Carresi, C.; Parafati, M.; Aprigliano, S.; Russo, V.; Savoia, C.; Ziviani, E.; Musolino, V.; Morani, F.; et al. Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in astrocytes via NQO2/quinone oxidoreductase 2: Implications for neuroprotection. *Autophagy* 2015, 11, 1063–1080. [CrossRef]

161. He, X.; Yuan, W.; Li, Z.; Hou, Y.; Liu, F.; Feng, J. 6-Hydroxydopamine induces autophagic flux dysfunction by impairing transcription factor EB activation and lysosomal function in dopaminergic neurons and SH-SY5Y cells. *Toxicol. Lett.* 2018, 283, 58–68. [CrossRef]

162. Mitter, S.K.; Song, C.; Qi, X.; Mao, H.; Rao, H.; Akin, D.; Lewin, A.; Grant, M.; Dunn, W., Jr.; Ding, J.; et al. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. *Autophagy* 2014, 10, 1989–2005. [CrossRef] [PubMed]
163. Dhingra, A.; Bell, B.A.; Peachey, N.S.; Daniele, L.L.; Reyes-Reveles, J.; Sharp, R.C.; Jun, B.; Bazan, N.G.; Sparrow, J.R.; Kim, H.J.; et al. Microtubule-Associated Protein 1 Light Chain 3B, (LC3B) Is Necessary to Maintain Lipid-Mediated Homeostasis in the Retinal Pigment Epithelium. Front. Cell. Neurosci. 2018, 12, 351. [CrossRef] [PubMed]

164. Zhang, Y.D.; Zhao, J.J. TFEB Participates in the Aβ-Induced Pathogenesis of Alzheimer’s Disease by Regulating the Autophagy-Lysosome Pathway. DNA Cell Biol. 2015, 34, 661–668. [CrossRef] [PubMed]

165. Daniele, S.; Mangano, G.; Durando, L.; Ragni, L.; Martini, C. The Nootropic Drug A-Glyceryl-Phosphoryl-Ethanolamine Exerts Neuroprotective Effects in Human Hippocampal Cells. Int. J. Mol. Sci. 2020, 21, 941. [CrossRef]

166. Yang, Y.; Karsli-Uzunbas, G.; Poillet-Perez, L.; Sawant, A.; Hu, Z.S.; Zhao, Y.; Moore, D.; Hu, W.; White, E. Autophagy promotes mammalian survival by suppressing oxidative stress and p53. Genes Dev. 2020, 34, 688–700. [CrossRef]

167. Ichimura, Y.; Waguri, S.; Sou, Y.S.; Kageyama, S.; Hasegawa, J.; Ishimura, R.; Saito, T.; Yang, Y.; Kouno, T.; Fukutomi, T.; et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol. Cell. 2013, 51, 618–631. [CrossRef]

168. Taguchi, K.; Fujikawa, N.; Komatsu, M.; Ishii, T.; Unno, M.; Akaie, T.; Motohashi, H.; Yamamoto, M. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc. Natl. Acad. Sci. USA 2012, 109, 13561–13566. [CrossRef]

169. Di Martino, R.M.C.; Pruccoli, L.; Bisi, A.; Gobbi, S.; Rampa, A.; Martinez, A.; Pérez, C.; Martinez-Gonzalez, L.; Paglione, M.; Di Schiavi, E.; et al. Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson’s Disease. ACS Chem. Neurosci. 2020, 11, 2728–2740. [CrossRef]

170. Gao, J.; Wang, L.; Liu, J.; Xie, F.; Su, B.; Wang, X. Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases. Antioxidants 2017, 6, 25. [CrossRef]

171. Panov, A.V.; Dikalov, S.I. Cardiolipin, Perhydroxyl Radicals, and Lipid Peroxidation in Mitochondrial Dysfunctions and Aging. Oxid. Med. Cell. Longev. 2020, 2020, 1323028. [CrossRef]

172. He, Y.; Jia, K.; Li, L.; Wang, Q.; Zhang, S.; Du, J.; Du, H. Salvianolic acid B attenuates mitochondrial stress against Aβ toxicity in primary cultured mouse neurons. Biochem. Biophys. Res. Commun. 2018, 498, 1066–1072. [CrossRef] [PubMed]

173. Ruffoli, R.; Bartalucci, A.; Frati, A.; Fornai, F. Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis. Front. Cell. Neurosci. 2015, 9, 341. [CrossRef] [PubMed]

174. Palikaras, K.; Tavernarakis, N. Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis. Exp. Gerontol. 2014, 56, 182–188. [CrossRef] [PubMed]

175. Ferese, R.; Lenzi, P.; Fulceri, F.; Biagioni, F.; Fabrizi, C.; Gambardella, S.; Familiari, P.; Frati, A.; Limanaqi, F.; Fornai, F. Quantitative Ultrastructural Morphometry and Gene Expression of mTOR-Related Mitochondriogenesis within Glioblastoma Cells. Int. J. Mol. Sci. 2020, 21, 4570. [CrossRef]

176. Valero, T. Mitochondrial biogenesis: Pharmacological approaches. Curr. Pharm. Des. 2014, 20, 5507–5509. [CrossRef]

177. Chin, L.S.; Olzmann, J.A.; Li, L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem. Soc. Trans. 2010, 38, 144–149. [CrossRef]

178. Nicholls, M.; Zhang, J.; Polster, B.M.; Elustondo, P.A.; Thirumaran, A.; Pavlov, E.V.; Robertson, G.S. Synergistic neuroprotection by epicatechin and quercetin: Activation of convergent mitochondrial signaling pathways. Neuroscience 2015, 308, 75–94. [CrossRef]

179. Cakir, Z.; Funk, K.; Lauterwasser, J.; Todt, F.; Zerbes, R.M.; Oelgeklaus, A.; Tanaka, A.; van der Laan, M.; Edlich, F. Parkin promotes proteasomal degradation of misregulated BAX. J. Cell Sci. 2017, 130, 2903–2913. [CrossRef]

180. Lu, S.; Sun, X.; Xu, L.; Sun, R.; Ma, Z.; Deng, X.; Liu, B.; Fu, Q.; Qu, R.; Ma, S. Baicalin attenuates in vivo and in vitro hyperglycemia-exacerbated ischemia/reperfusion injury by regulating mitochondrial function in a manner dependent on AMPK. Eur. J. Pharmacol. 2017, 815, 118–126. [CrossRef]

181. Wang, W.; Xu, J. Curcumin Attenuates Cerebral Ischemia-reperfusion Injury through Regulating Mitophagy and Preserving Mitochondrial Function. Curr. Neurovasc. Res. 2020, 17, 113–122. [CrossRef]
182. Chen, Y.; Chen, J.; Sun, X.; Shi, X.; Wang, L.; Huang, L.; Zhou, W. Evaluation of the neuroprotective effect of EGCG: A potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage. *Food Funct.* 2018, 9, 6349–6359. [CrossRef]

183. Yang, X.; Zhang, M.; Dai, Y.; Sun, Y.; Aman, Y.; Xu, Y.; Yu, P.; Zheng, Y.; Yang, J.; Zhu, X. Spermidine inhibits neurodegeneration and delays aging via the PINK1-PDR1-dependent mitophagy pathway in *C. elegans*. *Aging (Albany NY)* 2020, 12, 16852–16866. [CrossRef]

184. Ferrucci, M.; Ryskalin, L.; Biagioni, F.; Gambardella, S.; Busceti, C.L.; Falleni, A.; Lazzeri, G.; Fornai, F. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. *Brain Res.* 2017, 1184, 284–294. [CrossRef]

185. Toti, L.; Bartalucci, A.; Ferrucci, M.; Fulceri, F.; Lazzeri, G.; Lenzi, P.; Soldani, P.; Gobbi, P.; La Torre, A.; Gesi, M. High-intensity exercise training induces morphological and biochemical changes in skeletal muscles. *Biol. Sport.* 2013, 30, 301–309. [CrossRef] [PubMed]

186. Davinelli, S.; De Stefani, D.; De Vivo, I.; Scapagnini, G. Polyphenols as Caloric Restriction Mimetics Regulating Mitochondrial Biogenesis and Mitophagy. *Trends Endocrinol. Metab.* 2020, 31, 536–550. [CrossRef] [PubMed]

187. Jellinger, K.A. Interaction between pathogenic proteins in neurodegenerative disorders. *J. Cell. Mol. Med.* 2012, 16, 1166–1183. [CrossRef]

188. Higashi, S.; Iseki, E.; Yamamoto, R.; Minegishi, M.; Hino, H.; Fujisawa, K.; Togo, T.; Katsuse, O.; Uchikado, H.; Furukawa, Y.; et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. *Brain Res.* 2007, 1184, 284–294. [CrossRef]

189. Colom-Cadena, M.; Gelpi, E.; Charif, S.; Belbin, O.; Blesa, R.; Martí, M.J.; Clarimón, J.; Lleó, A. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. *Hum. Neuropathol. Exp. Neurol.* 2013, 72, 1203–1212. [CrossRef]

190. Charles, V.; Mezey, E.; Reddy, P.H.; Dehejia, A.; Young, T.A.; Polymeropoulos, M.H.; Brownstein, M.J.; Tagle, D.A. α-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. *Neurosci. Lett.* 2000, 289, 29–32. [CrossRef]

191. Takei, Y.; Oguchi, K.; Koshibara, H.; Hineno, A.; Nakamura, A.; Ohara, S. α-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. *Hum. Pathol.* 2013, 44, 1171–1176. [CrossRef]

192. Ling, S.C.; Polymenidou, M.; Cleveland, D.W. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. *Neuron* 2013, 79, 416–438. [CrossRef] [PubMed]

193. Trist, B.G.; Davies, K.M.; Cottam, V.; Genoud, S.; Ortega, R.; Roudeau, S.; Carmona, A.; De Silva, K.; Wäsinger, V.; Lewis, S.J.G.; et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain. *Acta Neuropathol* 2017, 134, 113–127. [CrossRef] [PubMed]

194. Ferrucci, M.; Ryskaln, L.; Biagioni, F.; Gambardella, S.; Busceti, C.L.; Falleni, A.; Lazzeri, G.; Fornai, F. Methamphetamine increases Prion Protein and induces dopamine-dependent expression of protease resistant PrPsc. *Arch. Ital. Biol.* 2017, 155, 81–97. [CrossRef] [PubMed]

195. da Luz, M.H.; Peres, I.T.; Santos, T.G.; Martins, V.R.; Icimoto, M.Y.; Lee, K.S. Dopamine induces the accumulation of insoluble prion protein and affects autophagic flux. *Front. Cell. Neurosci.* 2015, 9, 12. [CrossRef] [PubMed]

196. Martins, D.; English, A.M. SOD1 oxidation and formation of soluble aggregates in yeast: Relevance to sporadic ALS development. *Redox Biol.* 2014, 2, 632–639. [CrossRef] [PubMed]

197. Shimoto-Nagai, M.; Hisaka, S.; Naoi, M.; Maruyama, W. Modification of α-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: Its relevance to Parkinson disease. *J. Clin. Biochem. Nutr.* 2018, 62, 207–212. [CrossRef]

198. Vicente, M.H.; Outeiro, T.F. The sour side of neurodegenerative disorders: The effects of protein glycation. *J. Pathol.* 2010, 221, 13–25.

199. Adrover, M.; Maríño, L.; Sanchis, P.; Pauwels, K.; Kraan, Y.; Lebrun, P.; Vilanova, B.; Muñoz, F.; Broersen, K.; Donoso, J. Mechanistic insights in glycation-induced protein aggregation. *Biomacromolecules* 2014, 15, 3449–3462. [CrossRef]

200. Zhu, M.; Han, S.; Fink, A.L. Oxidized quercetin inhibits α-synuclein fibrillization. *Biochim. Biophys. Acta* 2013, 1830, 2872–2881. [CrossRef]
201. Medvedeva, M.; Barinova, K.; Melnikova, A.; Semenyuk, P.; Kolmogorov, V.; Gorelkin, P.; Erofeev, A.; Muronetz, V. Naturally occurring cinnamic acid derivatives prevent amyloid transformation of alpha-synuclein. Biochimie 2020, 170, 128–139. [CrossRef]

202. Taebnia, N.; Morshedi, D.; Yaghmaei, S.; Aliakbari, F.; Rahimi, F.; Arpanaei, A. Curcumin-loaded amine-functionalized mesoporous silica nanoparticles inhibit α-synuclein fibrillation and reduce its cytotoxicity-associated effects. Langmuir 2016, 32, 13394–13402. [CrossRef] [PubMed]

203. Šneideris, T.; Baranauskiene, L.; Cannon, J.G.; Rutkiene, R.; Meškys, R.; Smirnovas, V. Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives. Peer J. 2015, 3, e1271. [CrossRef] [PubMed]

204. Liu, Y.; Carver, J.A.; Calabrese, A.N.; Pukala, T.L. Gallic acid interacts with α-synuclein and decreases reactive oxidative stress. Neurochem. Int. 2005, 43, 280–300. [CrossRef] [PubMed]

205. Hafner-Bratkovic, I.; Gaspersic, J.; Smid, L.M.; Bresjanac, M.; Jerala, R. Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein—A new mechanism for the inhibition of PrPSc accumulation. J. Neurochem. 2008, 104, 1553–1564. [CrossRef] [PubMed]

206. Caughey, B.; Raymond, L.D.; Raymond, G.J.; Maxson, L.; Silveira, J.; Baron, G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 2003, 77, 5499–5502. [CrossRef] [PubMed]

207. Lin, C.F.; Yu, K.H.; Jheng, C.P.; Chung, R.; Lee, C.I. Curcumin reduces amyloid fibrillation of prion protein and decreases reactive oxidative stress. Proc. Natl. Acad. Sci. USA 2010, 107, 7710–7715. [CrossRef] [PubMed]

208. Ladiwala, A.R.A.; Lin, J.C.; Bale, S.S.; Marcelino-Cruz, A.M.; Bhattacharya, M.; Dordick, J.S.; Tessier, P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid a beta into o-pathway conformers. J. Biol. Chem. 2010, 285, 24228–24237. [CrossRef] [PubMed]

209. Ladner-Keay, C.L.; Ross, L.; Perez-Pineiro, R.; Zhang, L.; Bjorndahl, T.C.; Cashman, N.; Wishart, D.S. A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds. Prion 2018, 12, 280–300. [CrossRef]

210. Ono, K.; Hirohata, M.; Yamada, M. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochim. Biophys. Acta 2005, 1733, 444–449. [CrossRef]

211. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer’s disease. J. Neurochem. 2003, 87, 172–181. [CrossRef]

212. Hamaguchi, T.; Ono, K.; Murase, A.; Yamada, M. Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-beta aggregation pathway. Am. J. Pathol. 2009, 175, 2557–2565. [CrossRef] [PubMed]

213. Ladiwala, A.R.A.; Lin, J.C.; Bale, S.S.; Marcelino-Cruz, A.M.; Bhattacharya, M.; Dordick, J.S.; Tessier, P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid a beta into o-pathway conformers. J. Biol. Chem. 2010, 285, 24228–24237. [CrossRef] [PubMed]

214. Carver, J.A.; Calabrese, A.N.; Pukala, T.L. Gallic acid interacts with α-synuclein and decreases reactive oxidative stress. Neurochem. Int. 2005, 43, 280–300. [CrossRef] [PubMed]

215. Ladiwala, A.R.A.; Lin, J.C.; Bale, S.S.; Marcelino-Cruz, A.M.; Bhattacharya, M.; Dordick, J.S.; Tessier, P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid a beta into o-pathway conformers. J. Biol. Chem. 2010, 285, 24228–24237. [CrossRef] [PubMed]

216. Habtemariam, S. Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer’s and Vascular Dementia Drugs. Int. J. Mol. Sci. 2018, 19, 458. [CrossRef]

217. Habtemariam, S. Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer’s and Vascular Dementia Drugs. Int. J. Mol. Sci. 2018, 19, 458. [CrossRef]

218. Dariya, B.; Nagaraju, G.P. Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discov. Today 2020, 25, 1614–1623. [CrossRef]

219. Rebollo-Hernanz, M.; Fernández-Gómez, B.; Herrero, M.; Aguilera, Y.; Martín-Cabrejas, M.A.; Uribarri, J.; Del Castillo, M.D. Inhibition of the Maillard Reaction by Phytochemicals Composing an Aqueous Coffee Silverskin Extract via a Mixed Mechanism of Action. Foods 2019, 8, 438. [CrossRef]
220. Jiang, T.F.; Zhang, Y.J.; Zhou, H.Y.; Wang, H.M.; Tian, L.P.; Liu, J.; Ding, J.Q.; Chen, S.D. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson’s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. *J. Neuroimmune Pharmacol.* 2013, 8, 356–369. [CrossRef]  
221. Buratta, S.; Chiaradina, E.; Tognoloni, A.; Gambelunghe, A.; Meschini, C.; Palmieri, L.; Muzzi, G.; Urbanelli, L.; Emiliani, C.; Tancini, B. Effect of Curcumin on Protein Damage Induced by Rotenone in Dopaminergic PC12 Cells. *Int. J. Mol. Sci.* 2020, 21, 2761. [CrossRef]  
222. Lyman, M.; Lloyd, D.G.; Ji, X.; Vizcaychipi, M.P.; Ma, D. Neuroinflammation: The role and consequences. *Neurosci. Res.* 2014, 75, 1–12. [CrossRef]  
223. Maiti, P.; Rossignol, J.; Dunbar, G.L. Curcumin Modulates Molecular Chaperones and Autophagy-Lysosomal Pathways In Vitro after Exposure to Aβ42. *J. Alzheimers Dis. Parkinsonism*. 2017, 7, 299. [CrossRef]  
224. Jiang, T.F.; Zhang, Y.J.; Zhou, H.Y.; Wang, H.M.; Tian, L.P.; Liu, J.; Ding, J.Q.; Chen, S.D. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson’s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. *J. Neuroimmune Pharmacol.* 2013, 8, 356–369. [CrossRef]  
225. Jiang, W.; Wei, W.; Gaertig, M.A.; Li, S.; Li, X.-J. Therapeutic E... of the immunoproteasome subunit Lmp7 links proteostasis and immunity in α-synuclein aggregation disorders. *EBioMedicine* 2018, 31, 307–319. [CrossRef] [PubMed]  
226. Jiang, W.; Wei, W.; Gaertig, M.A.; Li, S.; Li, X.-J. Therapeutic E... of the immunoproteasome subunit Lmp7 links proteostasis and immunity in α-synuclein aggregation disorders. *EBioMedicine* 2018, 31, 307–319. [CrossRef] [PubMed]  
227. Lyman, M.; Lloyd, D.G.; Ji, X.; Vizcaychipi, M.P.; Ma, D. Neuroinflammation: The role and consequences. *Neurosci. Res.* 2014, 75, 1–12. [CrossRef]  
228. Regitz, C.; Dußling, L.M.; Wenzel, U. Amyloid-beta (Aβ1–42)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. *Mol. Nutr. Food Res.* 2014, 58, 1931–1940. [CrossRef] [PubMed]  
229. Cebrián, C.; Zucca, F.A.; Mauri, P.; Steinbeck, J.A.; Studer, L.; Scherzer, C.R.; Kanter, E.; Budhu, S.; Mandelbaum, J.; Vonsattel, J.P.; et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. *Nat. Commun.* 2014, 5, 3633. [CrossRef]  
230. Ugras, S.; Daniels, M.J.; Fazelinia, H.; Gould, N.S.; Yocum, A.K.; Luk, K.C.; Luna, E.; Ding, H.; McKennan, C.; Seeholzer, S.; et al. Induction of the immunoproteasome subunit Lmp7 links proteostasis and immunity in α-synuclein aggregation disorders. *EBioMedicine* 2018, 31, 307–319. [CrossRef] [PubMed]  
231. Regitz, C.; Dußling, L.M.; Wenzel, U. Amyloid-beta (Aβ1–42)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. *Mol. Nutr. Food Res.* 2014, 58, 1931–1940. [CrossRef] [PubMed]  
232. Chen, C.; Zou, L.X.; Lin, Q.Y.; Yan, X.; Bi, H.L.; Xie, X.; Wang, S.; Wang, Q.S.; Zhang, Y.L.; Li, H.H. Resveratrol β-catalytic... of the immunoproteasome subunit Lmp7 links proteostasis and immunity in α-synuclein aggregation disorders. *EBioMedicine* 2018, 31, 307–319. [CrossRef] [PubMed]  
233. Deretic, V.; Levine, B. Autophagy balances inflammation in innate immunity. *Autophagy* 2018, 14, 243–251. [CrossRef] [PubMed]  
234. Xue, Z.; Zhang, Z.; Liu, H.; Li, W.; Guo, X.; Zhang, Z.; Liu, Y.; Jia, L.; Li, Y.; Ren, Y.; et al. lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation. *Cell Death Differ.* 2019, 26, 130–145. [CrossRef] [PubMed]  
235. Singh, S.; Jamwal, S.; Kumar, P. Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. *Neural Regen. Res.* 2017, 12, 1137–1144. [CrossRef]  
236. Cuzzocrea, S. 2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease. *Mol. Neurobiol.* 2014, 58, 26–34. [CrossRef] [PubMed]  
237. Du, Y.; Luo, M.; Du, Y.; Xu, M.; Yao, Q.; Wang, K.; He, G. Liquiritigenin Decreases Aβ Levels and Ameliorates Cognitive Decline by Regulating Microglia M1/M2 Transformation in AD Mice. *Neurotox. Res.* 2020. Epub ahead of print. [CrossRef]
238. Chen, L.; Pan, H.; Bai, Y.; Li, H.; Yang, W.; Lin, Z.X.; Cui, W.; Xian, Y.F. Gelsemine, a natural alkaloid extracted from Gelsemium elegans Benth. alleviates neuroinflammation and cognitive impairments in Aβ oligomer-treated mice. *Psychopharmacology (Berl).* 2020, 237, 2111–2124. [CrossRef] [PubMed]

239. Yang, E.J.; Mahmood, U.; Kim, H.; Choi, M.; Choi, Y.; Lee, J.P.; Cho, J.Y.; Hyun, J.W.; Kim, Y.S.; Chang, M.J.; et al. Phloroglucinol ameliorates cognitive impairments by reducing the amyloid β peptide burden and pro-inflammatory cytokines in the hippocampus of 5XFAD mice. *Free Radic. Biol. Med.* 2018, 126, 221–234. [CrossRef] [PubMed]

240. Mattioli, R.; Francioso, A.; d’Erme, M.; Trovato, M.; Mancini, P.; Piacentini, L.; Casale, A.M.; Wessjohann, L.; Gazzino, R.; Costantino, P.; et al. Anti-Inflammatory Activity of A Polyphenolic Extract from *Arabidopsis thaliana* in In Vitro and In Vivo Models of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2019, 20, 708. [CrossRef] [PubMed]

241. Fusco, R.; Scuto, M.; Cordaro, M.; Fusco, R.; Siracusa, R.; Crupi, R.; Esposito, E.; Cuzzocrea, S. N-Palmitoylethanolamide-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury. *J. Neurotrauma* 2017, 34, 2609–2623. [CrossRef] [PubMed]

242. Gugliandolo, E.; D’Amico, R.; Cordaro, M.; Fusco, R.; Siracusa, R.; Crupi, R.; Impellizzeri, D.; Cuzzocrea, S.; Di Paola, R. Neuroprotective Effect of Artesunate in Experimental Model of Traumatic Brain Injury. *Front. Neurol.* 2018, 9, 590. [CrossRef] [PubMed]

243. Gao, Y.; Zhuang, Z.; Lu, Y.; Tao, T.; Zhou, Y.; Liu, G.; Wang, H.; Zhang, D.; Wu, L.; Dai, H.; et al. Curcumin Mitigates Neuro-Inflammation by Modulating Microglia Polarization Through Inhibiting TLR4 Axis Signaling Pathway Following Experimental Subarachnoid Hemorrhage. *Front. Neurosci.* 2019, 13, 1223. [CrossRef] [PubMed]

244. Fusco, R.; Scuto, M.; Cordaro, M.; D’Amico, R.; Gugliandolo, E.; Siracusa, R.; Peritore, A.F.; Crupi, R.; Impellizzeri, D.; Cuzzocrea, S.; et al. N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway. *Int. J. Mol. Sci.* 2019, 20, 4845. [CrossRef] [PubMed]

245. Caltagirone, C.; Cisari, C.; Schievano, C.; Di Paola, R.; Cordaro, M.; Buschetta, G.; Esposito, E.; Cuzzocrea, S.; Stroke Study Group. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: From Rodent to Man. *Transl. Stroke Res.* 2016, 7, 54–69. [CrossRef] [PubMed]

246. Bozkurt, A.A.; Mustafa, G.; Tark, A.; Adile, O.; Murat, S.H.; Mesut, K.; Yildray, K.; Coskun, S.; Murat, C. Syringaldehyde exerts neuroprotective effect on cerebral ischemia injury in rats through anti-oxidative and anti-apoptotic properties. *Neural Regen. Res.* 2014, 9, 1884–1890. [CrossRef] [PubMed]

247. Khan, A.; Ali, T.; Rehman, S.U.; Khan, M.S.; Alam, S.I.; Ikram, M.; Muhammad, T.; Saeed, K.; Badshah, H.; Kim, M.O. Neuroprotective Effect of Quercetin Against the Detrimental Effects of LPS in the Adult Mouse Brain. *Front. Pharmacol.* 2018, 9, 1383. [CrossRef] [PubMed]

248. Koza, L.A.; Winter, A.N.; Holsopple, J.; Baybayan-Grandgeorge, A.N.; Pena, C.; Olson, J.R.; Mazzarino, R.C.; Patterson, D.; Linseman, D.A. Protocatechuic Acid Extends Survival, Improves Motor Function, Diminishes Gliosis, and Sustains Neuromuscular Junctions in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. *Nutrients* 2019, 12, 1824. [CrossRef]

249. Winter, A.N.; Ross, E.K.; Wilkins, H.M.; Stankiewicz, T.R.; Wallace, T.; Miller, K.; Linseman, D.A. An anthocyanin-enriched extract from strawberries delays disease onset and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. *Nutr. Neurosci.* 2018, 21, 414–426. [CrossRef] [PubMed]

250. Huang, Q.; Ye, X.; Wang, L.; Pan, J. Salvianolic acid B abolished chronic mild stress-induced depression through suppressing oxidative stress and neuro-inflammation via regulating NLRP3 inflammasome activation. *J. Food Biochem.* 2019, 43, e12742. [CrossRef] [PubMed]

251. Yu, H.; Zhang, F.; Guan, X. Baicalin reverse depressive-like behaviors through regulation SIRT1-NF-kB signalling pathway in olfactory bulb-circumscribed rats. *Phytother. Res.* 2019, 33, 1480–1489. [CrossRef] [PubMed]

252. Limanaqi, F.; Biagioni, F.; Busceti, C.L.; Polzella, M.; Fabrizi, C.; Fornai, F. Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea. *Antioxidants* 2020, 9, 234. [CrossRef] [PubMed]

253. Testa, G.; Gamba, P.; Badilli, U.; Gargiulo, S.; Maina, M.; Guina, T.; Calafipietra, S.; Biasi, F.; Cavalli, R.; Poli, G.; et al. Loading into nanoparticles improves quercetin’s efficacy in preventing neuroinflammation induced by oxysterols. *PLoS ONE* 2014, 9, e96795. [CrossRef] [PubMed]
254. Silswal, N.; Reddy, N.S.; Qureshi, A.A.; Qureshi, N. Resveratrol Downregulates Biomarkers of Sepsis Via Inhibition of Proteasome’s Proteases. *Shock* **2018**, *5*, 579–588. [CrossRef] [PubMed]

255. Zhou, Z.D.; Xie, S.P.; Saw, W.T.; Ho, P.G.H.; Wang, H.; Lei, Z.; Yi, Z.; Tan, E.K. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson’s Disease (PD). *Cells* **2019**, *8*, 911. [CrossRef]

256. Farkhondeh, T.; Pourbagher-Shahri, A.M.; Ashrafizadeh, M.; Foltgado, S.L.; Rajabpour-Sanati, A.; Khazdair, M.R.; Samarghandian, S. Green tea catechins inhibit microglial activation which prevents the development of neurological disorders. *Neural Regen. Res.* **2020**, *15*, 1792–1798.

257. Bai, D.; Jin, G.; Zhang, D.; Zhao, L.; Wang, M.; Zhu, Q.; Zhu, L.; Sun, Y.; Liu, X.; Chen, X.; et al. Natural silibinin modulates amyloid precursor protein processing and amyloid-β protein clearance in APP/PS1 mice. *J. Physiol. Sci.* **2019**, *69*, 643–652. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).